Trading Analysis Report: ADBE¶

Analysis date: 2026-10-14
Rating: Underweight
Generated: 2026-10-15 00:20:27
TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 240.68 Price As Of: 2026-10-14

ADBE (Adobe Inc., NMS) – Technical Analysis Report¶

1. Summary¶

ADBE is stabilizing and bouncing short-term inside a still-damaged larger trend. The weekly SuperTrend is UP. The monthly and daily SuperTrends are both DOWN. Price sits below the 50 SMA and 200 SMA, and those two averages have just crossed each other. Momentum is recovering (MACD histogram positive, RSI off its lows), but it is not yet confirmed by volume or by a daily trend flip. Nothing is statistically stretched. This is a decision zone, not a trend extreme.

All indicator values below were checked against the verified snapshot. The 50 SMA, 200 SMA, RSI, MACD and ATR values match, so I found no discrepancies.

2. Indicators Selected and Why¶

I picked eight indicators with little overlap:

Trend: close_50_sma, close_200_sma, supertrend (weekly, monthly and daily tiers).
Momentum: macd and rsi. The snapshot also gives the MACD signal and histogram.
Volatility: atr, for stop sizing.
Volume: obv, to check whether volume confirms the price moves.
Stretch: z_score on three timeframes, to show whether price is extended.

I did not pull td_9 or adx because of the eight-indicator limit. So I can't give a DeMark count or a trend-strength reading.

3. Price Structure (from the OHLCV data)¶

The year-long decline: The closing high in the window was 359.91 on 2025-10-28. The closing low was 193.41 on 2026-06-25, and the intraday low was 190.12 on 2026-06-18. The current close is about 33% below the high and about 24% above the closing low.
Heavy-volume breaks:
2026-03-13: close 249.32 versus 269.78 the day before, on 17.4M shares.
2026-06-11 and 06-12: closes of 218.80 and then 204.02, on 17.8M and 25.0M shares. The 25.0M is the highest volume in the dataset.
The summer rally: Price went from 193.41 on 2026-06-25 to 292.79 on 2026-08-31, a gain of about 51%.
The retracement: Price then fell to 231.01 on 2026-09-28, a drop of about 21% from the August peak. That gives back roughly 62% of the rally on a closing basis (my arithmetic from the closes above). I'm noting it as context, not as a validated level.
Current consolidation: Closes since 2026-09-29 have stayed between 231.01 and 242.27. The swing low is the 224.67 intraday low on 2026-09-28. A higher intraday low of 227.00 followed on 2026-10-07.
Today's bar: The open (235.90) was the low of the day and the close (240.68) was near the high of 241.25. The day gained about 1.9% from 236.28. Volume was 3.48M, which is light. My arithmetic puts the average of the last 10 sessions at about 4.2M, so today's bounce had thin participation.

4. Trend Analysis¶

Moving averages (snapshot-verified) - The 50 SMA is 257.00 and the 200 SMA is 255.26. Price is about 6% below the 50 SMA and about 6% below the 200 SMA. - The 10 EMA is 239.14 and the Bollinger middle is 239.78. Price is just above both, which means short-term trend is flat. - The 200 SMA has fallen steadily from 266.34 on 2026-09-14 to 255.26 now, a decline of about 4%. - The 50 SMA peaked at 258.77 on 2026-10-06 and is now rolling over, with a 30-day range of 253.53 to 258.77. - On this series the 50 SMA moved above the 200 SMA on 2026-10-06. On 10-05 it was 258.76 against 259.33, and on 10-06 it was 258.77 against 258.74. The gap is now only 1.74. - This is a "golden cross" in name only. The 200 SMA falling toward price caused it, price is below both averages, and the 50 SMA is itself declining. I would not treat it as a bullish signal until price reclaims both averages.

SuperTrend (tiers weighted weekly > monthly > daily)

Tier	Direction	Stop	Close vs. stop
Weekly (primary)	UP	206.08	+16.79%
Monthly (regime)	DOWN	400.90	−39.97%
Daily (timing)	DOWN	256.93	−6.33%

The primary weekly tier is up, so by the tiering rule it carries the most weight. Its stop sits far below, near the June washout area.
The monthly tier is down with a stop far above, which says the multi-year regime is still bearish. A monthly flip is not a near-term event.
The daily stop at 256.93 sits almost on top of the 50 SMA (257.00) and just above the 200 SMA (255.26). That makes a tight resistance cluster of about 255.3 to 257.0, roughly 6% overhead. A daily close above it would flip the daily SuperTrend and reclaim both averages at once.

5. Momentum¶

MACD: The MACD line is −4.67, the signal is −5.58 and the histogram is +0.91. The MACD line has risen from −7.94 on 2026-09-29. It is above its signal line but still below zero. That fits a momentum recovery inside a larger downtrend, not a confirmed trend change.
RSI: RSI is 46.56, a neutral reading. It fell as low as 34.51 on 2026-09-28 and 38.00 on 2026-10-07. The 10-07 trough was higher than the 09-28 trough, matching the higher price low. That is mild improvement, not a classic divergence. RSI has not been above 50 in the window since 50.56 on 2026-09-14, and it needs to clear 50 to confirm improving momentum.

6. Volatility and Risk Sizing¶

ATR is 8.26, about 3.4% of price. It has contracted from 11.06 on 2026-09-14, so the sharp swings of early and mid September have calmed.
The Bollinger bands are 228.82 (lower), 239.78 (middle) and 250.74 (upper). Price is just above the middle band and has plenty of room to either band.
A 2×ATR stop below the current close would be around 224.2. That is near the 2026-09-28 intraday low of 224.67 and below the 10-07 low of 227.00. A stop around 224 to 225 therefore sits just under the recent swing lows. A 1.5×ATR stop would be about 228.3, close to the lower Bollinger band.
With a 3.4% daily ATR, the move to the 255–257 resistance cluster is about 2 ATR. This gives a rough sense of reward-to-risk for a long entry here.

7. Volume (OBV)¶

OBV is −202.5M, compared with −187.0M on 2026-09-14. It is down about 15M over the window. The absolute level is not meaningful.
OBV hit a low of −211.8M on 2026-09-28 and has recovered a little. The 10-07 low of −207.5M was higher than the 09-28 low, consistent with the price pattern.
OBV is not yet back at its 2026-10-01 level (−198.4M), and price is slightly below its 10-01 close as well. That is broadly confirming but not decisive. Volume has not yet shown accumulation, and today's bounce came on light volume.

8. Stretch (Z-Score)¶

Weekly is −0.03, monthly is −1.09 and daily is +0.16. None reaches the |z| ≥ 2 stretch threshold.
The weekly reading near zero says price is at its 20-week mean, so there is no mean-reversion edge in either direction. The monthly −1.09 says price is still below its 20-month mean, consistent with the bearish monthly regime. Neither reading suggests an extreme.

9. Levels to Watch¶

Type	Level	Basis
Resistance	242.27, 245.16	2026-10-09 close and high
Resistance	248.3	2026-10-01 intraday high
Resistance	250.74	Upper Bollinger band
Resistance	255.3–257.0	200 SMA, daily SuperTrend, 50 SMA
Resistance	265.6–266.1	2026-09-14 close and high
Support	235.5–236.3	Recent closes (2026-10-13 and 09-25)
Support	228.8	Lower Bollinger band
Support	224.67 and 227.00	09-28 and 10-07 intraday lows
Support	206.08	Weekly SuperTrend stop
Support	190.12	2026-06-18 intraday low

I'm not claiming any of these levels has held or failed historically. They are just where the data places them.

10. Scenarios¶

Bullish: A daily close above about 257 would flip the daily SuperTrend and reclaim both averages. It would line up with the weekly UP trend and tighten the case for a recovery toward the 265–266 area and higher. Look for RSI above 50, a rising OBV and above-average volume to confirm.
Bearish: A close below about 227 to 224 would break the series of higher lows and put the 2026-09-28 low at risk. The weekly SuperTrend at 206.08 would then be the main trend line left. Rising volume on a decline would add weight.
Base case: Continued range-bound trading between about 228 and 250, with the 10 EMA and Bollinger middle (about 239 to 240) acting as the pivot. Declining ATR supports this.

11. Caveats¶

The multi-timeframe picture conflicts (weekly up, monthly and daily down), so treat any trade as lower conviction until the daily trend aligns with the weekly.
The bounce is light on volume and still below all the key averages.
Event risk is not captured here. The big gaps in the data (2026-03-13, 2026-06-12, 2026-08-27 and others) coincided with very large volume. The data does not say why, so earnings and news should be checked separately.
I did not pull ADX, so I can't state trend strength. I also did not pull td_9.

12. Key Points Table¶

Category	Indicator	Reading (as of 2026-10-14)	Interpretation
Price	Close / range	240.68 (O 235.90, H 241.25, L 235.90, V 3.48M)	Closed near the high on light volume
Trend	50 SMA	257.00	Price about 6% below; rolling over
Trend	200 SMA	255.26	Falling; 50 SMA crossed above it on 10-06 (weak signal)
Trend	SuperTrend weekly	UP, stop 206.08 (+16.79%)	Primary tier is bullish
Trend	SuperTrend monthly	DOWN, stop 400.90 (−39.97%)	Long-term regime bearish
Trend	SuperTrend daily	DOWN, stop 256.93 (−6.33%)	Flip needs a close above ~257
Momentum	MACD / signal / hist	−4.67 / −5.58 / +0.91	Recovering, still below zero
Momentum	RSI	46.56	Neutral; low was 34.51 on 09-28
Volatility	ATR	8.26 (~3.4% of price)	Contracting from 11.06 on 09-14
Volatility	Bollinger (L / M / U)	228.82 / 239.78 / 250.74	Price just above the middle band
Volume	OBV	−202.5M	Off 09-28 low (−211.8M), not yet accumulating
Stretch	Z-score (W / M / D)	−0.03 / −1.09 / +0.16	Nothing stretched
Short-term	10 EMA	239.14	Price marginally above
Resistance	Cluster	255.3–257.0	200 SMA, 50 SMA, daily SuperTrend
Support	Swing lows	224.67 (09-28), 227.00 (10-07)	Near the 2×ATR stop (~224.2)
Overall	Bias	Mixed / neutral, improving short-term	Weekly up, monthly and daily down

Sentiment Analyst¶

Overall Sentiment: Mixed (Score: 5.0/10) Confidence: Low

Scope and data limits. Window: 2026-10-07 to 2026-10-14 for ADBE (Adobe Inc.). Three inputs were planned. Yahoo Finance gave 20 headlines (titles and links only, no article bodies). StockTwits gave 27 messages. Reddit was skipped by config, so there is no read from r/wallstreetbets, r/stocks or r/investing. No price, volume, options or fundamentals data were supplied, so every price level below is a retail-user claim and unverified. Confidence is low because one source is missing, the news is headline-only and the social sample is thin.

1. Source-by-source breakdown

News (20 headlines). About eight concern the HSBC analyst action. HSBC downgraded ADBE to Hold from Buy with a $267 price target (MT Newswires), citing growing AI software-disruption risk (TIKR, GuruFocus: 'Adobe Stock Slips'). HSBC also flagged headline risk from a free software clone (Investing.com). The Fly, Barchart and a 24/7 Wall St. 'Tuesday's top analyst calls' roundup carried the same call. Stocktwits' premarket movers piece listed ADBE sliding alongside MU and ASTS on a 'China chip threat' plus downgrades. Since the roundup is labeled Tuesday (2026-10-13), the downgrade and initial slide most likely hit on 10/13. That is an inference, as dates are not in the data. Two headlines are fundamentals-cautious: TheStreet says the free-user bet shows 'cracks' ahead of a CEO handoff, and Trefis asks 'What Is Adobe No Longer Telling You?'. Four are constructive or contrarian: Insider Monkey on the high-margin platform and free cash flow; Insider Monkey on ADBE trading under 10x earnings and whether AI fear is overdone; 24/7 Wall St. arguing the cannibalization threat 'isn't real'; and Motley Fool on software stocks down more than 35% from records. Two are neutral or comparative (ADBE vs ADSK and CRM on Firefly/GenStudio; AI cannibalization hitting Salesforce and Adobe differently). Four are peripheral and carry no ADBE signal (two Trefis Salesforce pieces, one Shopify piece, a BeatViz AI music-video press release). Net: the discrete institutional event is negative, but editorial reaction is split, with a visible 'overreaction / deep value' counter-narrative. Because only titles were provided, HSBC's full reasoning, the CEO-transition details and what Adobe is 'no longer telling' investors cannot be assessed.

StockTwits (27 messages, 17 unique authors, all timestamped 2026-10-14, roughly 18:13Z to 23:57Z). Tags: 8 Bullish (30%), 2 Bearish (7%), 17 unlabeled (63%). One bullish tag (@ezekeil) is about $SOXX, not ADBE, so on-topic labeled posts are 7 bullish vs 2 bearish (about 78/22). That is only 9-10 labeled posts, so the ratio is fragile. It is bullish-leaning but not at the 90/10 over-extension level. Author concentration matters: @dumbcat posted 5 times, @Prady 3 (all bullish) and @SXTwhale 3, so the bullish tags come from just 5 distinct on-topic authors. Bullish content: @Prady says ADBE closed above its 20-day MA with the 50/200-day near 255-257 and is waiting for money to rotate from chips and AI into software. @itsmeo51 mentions a prior high of 293 and says about 5 new posters have started shorting after the stock was already punished to single-digit multiples. @Rocketman808 calls it an undervalued, solid-cash-flow business. @algotradealert says risk looks mostly priced in, though AI worry may cap the stock. @KornieAwareness7 sees non-AI-adjacent software (INTU, ADBE, NOW) perking up in case 'AI magic is over'. @Prady also floats a Microsoft buyout, which is speculative and unsupported. Bearish content: @SXTwhale is a put holder complaining of 'burning the puts' and expecting a late-day flush. @opticaldog says MSFT and ADBE lost the ability to hire foreign workers, an unverified single post. The unlabeled majority is mixed and often sarcastic ('LMAO', 'Rekt'). Several posts carry the AI-replacement thesis: @Burky90 says a single person with a Claude subscription can recreate products built over 30 years, @Punit says someone made the Adobe and Microsoft suite apps free/open-source via the REA (Reverse Engineer Anything) repo, and @dumbcat expects agencies to stop renewing subscriptions. Others are tentative-bullish ('some buyers here', 'headed back to 250 soon', which is ambiguous but implies price is below 250). @stockmando is wait-and-see. The sample covers one session, so it captures the reaction to the downgrade rather than a full week of sentiment.

Reddit. Not available (disabled by config). No read on Reddit sentiment is possible.

2. Cross-source divergences and alignments

Divergence: news flow is event-driven and negative (downgrade, AI-disruption framing, CEO handoff, free-user concerns), while the labeled StockTwits tags lean bullish and describe a bounce, dip-buying and a valuation floor. Alignment: both sources share the same underlying debate. The AI/free-clone cannibalization fear (HSBC's headline risk; retail citing the REA repo) is set against a sub-10x earnings and free-cash-flow value case (Insider Monkey, 24/7 Wall St.; @Rocketman808, @algotradealert). Retail bulls are largely echoing the valuation-overreaction argument already present in the news rather than offering independent evidence. The unlabeled posts show that much retail chatter still accepts the disruption premise even where tags are bullish. If the retail-cited levels are accurate, the $267 Hold target would sit above the quoted 50/200-day zone, but no price data was provided to confirm that.

3. Dominant narrative themes

(a) AI disruption and cannibalization of creative software, including the free open-source clone narrative. (b) Deep-value setup: under 10x earnings, strong FCF, down more than 35% from records. © Technical rebound and possible rotation from AI/chip names (which sold off on the China chip headline) into non-AI-adjacent software. (d) Leadership transition and execution, via the CEO handoff and free-user monetization. (e) Low-quality noise, such as the Microsoft buyout chatter and the foreign-worker hiring post.

4. Catalysts and risks

Catalysts: One retail user cites a large November event in Miami with new product announcements and December earnings. Neither is in the news data, so treat both as unverified. Other catalysts are details on the CEO succession, evidence that Firefly/GenStudio monetizes, and continued rotation into software. Risks: further analyst downgrades and a sticky AI-disruption narrative. The open-source clone story could go viral again, and HSBC explicitly flagged this headline risk. Others are agency or enterprise seat non-renewal (anecdotal only), free-user monetization problems and leadership-transition execution. Positioning is two-sided, with put holders and new shorts on the board, so squeezes or flushes are possible in either direction. Past sentiment is not predictive, and this should be weighed alongside fundamentals and technicals.

5. Summary table

Signal	Direction	Source	Evidence
HSBC downgrade to Hold, $267 PT	Bearish	News (MT Newswires, TIKR, The Fly, Barchart, GuruFocus)	Cited AI software-disruption risk; ADBE slid premarket alongside MU and ASTS
Free software clone / open-source suite headline risk	Bearish	News (Investing.com) and StockTwits (@Punit, @Burky90)	HSBC flags headline risk; retail cites the REA repo and 'one person with a Claude subscription'
CEO handoff and free-user 'cracks'	Cautious / Bearish	News (TheStreet, Trefis)	Headline-only; no details on the handoff or the disclosure change
Sub-10x earnings and FCF value case	Bullish	News (Insider Monkey, 24/7 Wall St., Motley Fool) and StockTwits (@Rocketman808, @algotradealert)	'Is the AI fear overdone?'; 'threat isn't real'; 'risk looks mostly priced in'
Labeled retail ratio	Mildly Bullish (thin sample)	StockTwits	8 Bull / 2 Bear / 17 unlabeled of 27; 7:2 on-topic; 17 authors, 5 bullish
Technical bounce and rotation into non-AI software	Mildly Bullish	StockTwits (@Prady, @KornieAwareness7)	Close above 20-day MA; 50/200-day near 255-257; INTU and NOW also green (unverified)
Put and short positioning	Mixed / Contrarian	StockTwits (@SXTwhale, @itsmeo51)	'burning the puts'; about 5 new shorts noted after the drop
Agency subscription non-renewal	Bearish	StockTwits (@dumbcat)	Single anecdotal claim
Microsoft buyout and foreign-hiring posts	Noise	StockTwits (@Prady, @opticaldog)	Speculative or unverified, single posts
Reddit sentiment	No data	Reddit	Disabled by config

Bottom line: Mixed. A negative institutional event and an unresolved AI-disruption debate are offset by a valuation-driven retail bounce and a contrarian news counter-narrative. The sample is thin, covers one session and lacks Reddit, so the read is low-confidence.

News Analyst¶

ADBE (Adobe Inc.): news and macro report, week of 2026-10-07 to 2026-10-14¶

Data coverage¶

FRED macro data failed. Every FRED call returned a 403 error. That covers fed funds, 10-year yield, yield curve, CPI, unemployment, VIX and core PCE. I have no official figures for any of them, and I haven't estimated any. Macro color below comes only from news headlines and prediction markets.
News results are headlines only. They have no article text and no precise timestamps. I flag any date I inferred.
No price data. I have no ADBE quote, so I can't say where the stock trades relative to the $267 target below.
No earlier company news. The 2026-09-14 to 2026-10-06 lookup returned nothing. The tool says this reflects a sampling limit, not a lack of news.

1. ADBE company news¶

The main story is an analyst downgrade and the AI-disruption narrative. - HSBC downgrade. HSBC cut ADBE to Hold from Buy with a $267 price target (MT Newswires, The Fly, Barchart, GuruFocus, TIKR). Headlines say it was driven by "growing AI software disruption risks." Investing.com says HSBC also flagged "headline risk from a free software clone." - Likely timing. The downgrade appears alongside "Tuesday's top analyst calls" and a Stocktwits premarket-movers piece listing ADBE as sliding. That points to Tuesday, Oct 13, but this is my inference. - Market backdrop that day. The same premarket headline cites a "China chip threat" hitting MU and other names, so ADBE's drop came on a weak tech tape.

Sentiment is split, and the defenders are leaning on valuation. - Bullish or contrarian pieces: - 24/7 Wall St.: "Adobe is Being Punished for a Creative Cannibalization Threat That Isn't Real" - Insider Monkey: "Trades Under 10 Times Earnings. Is the AI Fear Overdone?" - Insider Monkey: a high-margin, free-cash-flow thesis - Motley Fool: lists ADBE among software stocks down more than 35% from their records - Cautious pieces: - TheStreet: Adobe's free-user bet "shows cracks before its CEO handoff" - Trefis: "What Is Adobe No Longer Telling You?" - 24/7 Wall St.: "AI Cannibalization Is Hitting Salesforce and Adobe In Very Different Ways" - Peer comparisons (Insider Monkey, vs. ADSK and CRM) frame the debate as whether Firefly and GenStudio can turn AI into sustained growth.

Items to verify before relying on them. - The "CEO handoff" is a headline reference only. I couldn't confirm the successor, timing or terms. - "Under 10x earnings" is an author's claim, and I can't tell which earnings measure it uses. - The "free-user bet" and "no longer telling you" pieces suggest Adobe changed some disclosure or metric. I can't tell what from the headlines.

2. Macro and market backdrop (headline-based)¶

Rates and inflation are the dominant theme. - Yahoo Finance: the 10-year Treasury yield rose after hot inflation data. - Bloomberg: hot inflation "lifts October rate-hike bets," and gold held its losses. - Yahoo Finance: global bond yields are surging, with France on "the ugly side." - Mortgage rates are at their highest in nearly three years, with "Is 8% next?" commentary. - A BofA fund manager survey says investors won't swap stocks for bonds until yields hit about 5.9%. The headline doesn't specify which yield.

Equities show valuation and risk-off caution. - BlackRock is "suddenly more bearish on stocks." - Yahoo Finance warns of "bubble-like valuations and debt crisis chatter." - Tech was hit by rising oil and chip weakness, then rebounded as AI-trade jitters eased. This is choppy, headline-driven tape. - Banks rose on JPMorgan and Goldman earnings, so earnings season is underway and financials are leading.

Energy and geopolitics. - Oil fell to about $103 after Trump said the US won't attack Iran before the midterms. Oil is still high in absolute terms, which feeds inflation. - The midterms are on Nov 3.

3. Prediction markets (Polymarket)¶

Market	Implied probability	Volume	Note
No Fed rate cuts in 2026	97%	~$8.9M	Deep market, +1.2pp on the week
Another Fed hike in 2026 (resolves Dec 10)	82%	~$0.78M	+5pp on the week
Exactly 1 / 2 / 3 hikes in 2026	18% / 66% / 18%	$0.14M–$0.43M	Thin; sums to about 102%. Modal outcome is 2 hikes.
US recession by end of 2026	8%	~$2.3M	+1pp on the week
US–Iran ceasefire holds through Oct 31	80%	~$3.0M	+8pp on the week
US invades Iran before 2027	16%	~$74M	Very deep market
US–Iran final nuclear deal by Dec 31	12%	~$3.5M
Adobe-specific markets	None	n/a	No coverage

Reading the hike markets. The market treats the Fed as a bias-to-tighten central bank. Cuts are essentially off the table, and further hikes are likely. The hike-count markets are thin, so treat the exact-count numbers as rough.
Missing context. I don't know the current fed funds level or how many hikes have already happened in 2026. FRED was unavailable.

4. Implications for ADBE (observations, not a trade call)¶

Rates are a headwind for software multiples. A hawkish Fed and rising long yields tend to compress valuations for software and growth stocks. If CPI keeps surprising high, that pressure could continue regardless of Adobe's fundamentals.
The AI-disruption story is the company-specific driver. The HSBC downgrade fits a pattern of sell-side concern about generative-AI substitutes for creative software. Further downgrades, or a visible free or cheap clone product, could extend the pressure. Evidence of Firefly and GenStudio monetization could counter it.
A cheap valuation doesn't guarantee a floor. Bulls cite a low multiple and strong free cash flow. Low multiples in disrupted sectors can stay low if growth estimates are cut. Estimate revisions are what to watch.
Leadership transition adds uncertainty. The CEO handoff headline means any announcement or strategy shift could move the stock. Details need verifying.
Macro tail risks.
Oil and inflation. An Iran flare-up would push oil and rate expectations higher. The market prices an 80% chance the ceasefire holds through Oct 31, which leaves meaningful residual risk.
Bond yields. A disorderly global move, such as the French stress cited, could hit equities broadly.

5. Catalysts to watch (verify dates independently)¶

Late-October FOMC. I recall it as Oct 27–28, but I couldn't confirm that with these tools. Bloomberg headlines say hike bets rose into it.
Big-tech and software earnings. Peers such as CRM and ADSK are discussed in Adobe coverage. Their results will shape the AI-disruption read-through.
Adobe's own events. Adobe usually holds its MAX conference in late October and reports fiscal Q4 results in December. I didn't confirm either date with the tools.
Nov 3 midterms. This matters for the Iran and oil narrative.
More analyst actions. Watch for follow-on rating or target changes after the HSBC downgrade.

6. Summary table¶

Category	Key point	Source type	Confidence / caveat
ADBE analyst action	HSBC downgraded to Hold from Buy, $267 target, citing AI disruption and clone headline risk	Multiple headlines	High on the fact; date inferred as about Oct 13
ADBE price reaction	Listed among premarket decliners on a weak tech tape	Stocktwits headline	Moderate; no price data
ADBE sentiment	Split: "cannibalization isn't real" and "under 10x earnings" vs. "cracks" and "no longer telling you"	Opinion pieces	Moderate; article text not retrieved
ADBE leadership	A CEO handoff is referenced	TheStreet headline	Low; details unverified
Rates and inflation	Hot inflation data lifted yields and October hike bets	Yahoo and Bloomberg headlines	Moderate; no FRED confirmation
Fed expectations	97% no cuts in 2026; 82% another hike by Dec 10	Polymarket	High on cuts; hike counts thin
Recession risk	US recession by end of 2026 at 8%	Polymarket	Moderate; low-probability tail
Global bonds and housing	Yields surging globally, mortgage rates near 3-year highs	Headlines	Moderate
Equity sentiment	BlackRock more bearish; bubble-valuation worries; tech choppy	Headlines	Moderate
Energy and geopolitics	Oil about $103; 80% chance the Iran ceasefire holds through Oct 31; 16% chance of a US invasion before 2027	Headline and Polymarket	Moderate
Macro data	FRED unavailable (403): no CPI, unemployment, yield, VIX or PCE values	Tool failure	Gap; another source is needed
Prediction markets for ADBE	None exist	Polymarket	n/a

Bottom line. ADBE faces two overlapping pressures: a company-specific AI-disruption downgrade cycle, and a macro backdrop with persistent inflation, hike expectations and rising yields. Valuation-based counterarguments exist, but the news flow I could see doesn't show a catalyst that resolves either pressure. The next assistant should fill the gaps with live price data, actual CPI, yield and VIX readings, and the details of the CEO transition and the HSBC note.

Fundamentals Analyst¶

ADBE (Adobe Inc.) Fundamental Report¶

Data as of 2026-10-14. The latest reported period is fiscal Q3 FY26, which ended 2026-08-28. Technology / Software – Application, NMS.

1. Scope and data caveats¶

No new insider filings in the past week. The most recent insider entries are dated 2026-09-15. The tools return no news or earnings-call text, so I can't link anything to a catalyst.
Fiscal Q4 (November) is missing from the quarterly income and cash-flow tables. Annual statements fill that gap. I derived Q4 FY25 as the annual figure minus the Q1–Q3 figures.
Quarterly cash flow is cumulative year-to-date (3, 6 and 9 months). I backed out the discrete quarters myself.
The price is not stated. I inferred about $240.7 from EPS (TTM) of 18.24 × P/E of 13.195. Please check it against a live quote.
Figures I calculated from the statements are marked "derived."

2. Snapshot and valuation (vendor figures)¶

Metric	Value	Comment
Market cap	$93.7B
Trailing P/E	13.2	Low for a ~35% operating-margin software company
Forward P/E	8.75	Forward EPS of $27.51 is 51% above TTM EPS of $18.24
PEG	0.57
Price/Book	8.0	Book value is $30.09/share and is shrunk by buybacks
Beta	1.415	Higher than the market
52-week range	$190.12 – $363.70	The inferred price is about 34% below the high and about 29% of the way up the range
50-day / 200-day average	$257.0 / $255.3	The inferred price is about 6% below both
Dividend yield	0%	Capital is returned through buybacks only
ROE / ROA	61.9% / 20.1%	ROE is inflated by the shrinking equity base (see section 5)
Margins	Operating 34.8%, net 28.0%	EBITDA is $9.92B (38% margin)
TTM revenue / net income	$25.97B / $7.28B
Free cash flow (vendor)	$9.35B	About a 10% FCF yield (derived)

The forward P/E is probably not comparable to the trailing one. A 51% jump from TTM to forward EPS is much larger than the roughly 10% GAAP EPS growth in the filings. It likely reflects non-GAAP estimates that exclude stock-based compensation and amortization. I can't confirm the basis from these tools. Treat 8.75x as a ceiling on how cheap the stock is, not a like-for-like figure.
The stock looks inexpensive on GAAP numbers. It trades at 13.2x GAAP earnings, about 3.6x sales and about 10x FCF. That points to a market debating durability, not to weak fundamentals.

3. Income statement¶

Annual history

FY	Revenue ($M)	YoY (derived)	Gross margin	Operating margin	Net income ($M)	Diluted EPS
2021	15,785	22.7%	88.2%	36.8%	4,822	10.02
2022	17,606	11.5%	87.7%	34.6%	4,756	10.10
2023	19,409	10.2%	87.9%	34.3%	5,428	11.82
2024	21,505	10.8%	89.0%	31.3% (includes a one-time ~$1B charge)	5,560	12.36
2025	23,769	10.5%	89.3%	36.6%	7,130	16.70

The FY24 dip matches the Q1 FY24 operating income of $907M and net income of $620M. The $1B charge is my inference from that quarterly drop, not something the tools state.

Recent quarters (fiscal Q1–Q3)

Quarter	Revenue	YoY	Gross margin	Operating income	Operating margin	Net income	EPS
Q1 FY26 (Feb-26)	6,398	+12.0%	89.6%	2,418	37.8%	1,889	4.60
Q2 FY26 (May-26)	6,618	+12.7%	89.2%	2,238	33.8%	1,712	4.25
Q3 FY26 (Aug-26)	6,760	+12.9%	88.7%	2,354	34.8%	1,827	4.62
Q3 FY25 (comparison)	5,988		89.3%	2,173	36.3%	1,772	4.18

All growth and margin figures above are derived.

What stands out 1. Growth is accelerating. Revenue growth was about 10.5% in FY25. It has moved from 12.0% to 12.7% to 12.9% across the three FY26 quarters. Nine-month revenue is up 12.5%. 2. Profit is growing more slowly than revenue. - Nine-month operating income is up about 8.8%. - Nine-month net income is up only about 2.9%. - Q3 operating margin was 34.8%, down about 150 bps from 36.3% a year earlier. - Nine-month operating margin was 35.4% against 36.7% a year earlier. 3. Cost of revenue is climbing faster than revenue. Its year-over-year growth went from +6.8% to +12.1% to +18.8% across the three quarters. Gross margin slipped from 89.6% to 89.2% to 88.7%. The tools don't say why. Rising compute or AI-delivery costs are one possible cause, but I can't verify that. 4. EPS growth leans on buybacks. Q3 net income grew 3.1%, but EPS grew 10.5%. Implied diluted shares fell from about 424M to about 395M, down about 7% (derived). 5. Net income lags operating income. The tools don't break out interest, other income or taxes. Lower cash balances (section 5) may reduce interest income, but that is a hypothesis to check in the 10-Q.

4. Cash flow¶

FY ($M)	Operating cash flow	Capex	FCF (derived)	FCF margin	Financing cash flow
2023	7,302	360	6,942	35.8%	−5,182
2024	8,056	183	7,873	36.6%	−7,724
2025	10,031	179	9,852	41.4%	−11,060

Fiscal 2026, first nine months - Operating cash flow was $7,646M, up 11.3% from $6,871M a year earlier. - Capex was $180M, so FCF was about $7,466M, up about 11% (derived). - Discrete quarters (derived):

Quarter	OCF FY26	OCF FY25	Change
Q1	2,958	2,482	+19%
Q2	2,165	2,191	−1%
Q3	2,523	2,198	+15%

Cash conversion is very high. Nine-month OCF of $7.65B is about 1.4x nine-month net income of $5.43B. Stock-based compensation and deferred revenue are the usual drivers, but the tools don't itemize them.
Capex is minimal, about 1% of revenue.
Financing outflows were $6.81B for nine months against $8.51B a year earlier. That is about 89% of OCF, a lower pace than in FY25, when it exceeded 100% of OCF. The tools don't split buybacks from debt activity.
Investing outflow was $1.91B for nine months, versus $1.04B a year earlier. The tools don't say what it was. It could be an acquisition or net investment purchases, so check the 10-Q.
The vendor and statement FCF figures disagree. The vendor shows $9.35B. TTM FCF from the statements (OCF $10.81B less capex $0.21B) is about $10.6B, 13% higher. The vendor figure may use a different definition. This implies an FCF yield of 10–11%.

5. Balance sheet (Aug 28, 2026, $M)¶

	Aug-26	Nov-25	Nov-24	Nov-23
Total assets	29,981	29,496	30,230	29,779
Cash & equivalents	4,359	5,431	7,613	7,141
Total liabilities	18,217	17,873	16,125	13,261
Current liabilities	11,888	10,200	10,521	8,251
Stockholders' equity	11,764	11,623	14,105	16,518

Liquidity is thin.
The current ratio is 0.77 (current assets $9,158M against current liabilities $11,888M).
Cash has fallen 43% from its November 2024 level.
Current liabilities are up 29% year over year, against revenue growth of about 13%. The tools don't itemize deferred revenue or the current portion of debt, so I can't say which is driving this.
A sub-1.0 current ratio is common for subscription software because of deferred revenue. With about $10B of annual FCF it is not alarming, but it leaves less flexibility.
Leverage has risen, but it is manageable.
Debt-to-equity is 57.7%, which implies roughly $6.8B of debt (derived).
Liabilities have grown 37% since November 2023 while equity is down 29% from its $16.5B peak.
Equity has been roughly flat since November 2025, as buybacks slowed and earnings kept pace.
The 61.9% ROE and 8.0x P/B largely reflect that smaller equity base, so don't read them as a pure quality signal.
Net debt is about $2.4B using cash only (derived). Short-term investments aren't shown in these tools, so this overstates net debt.

6. Insider activity (open-market trades since late 2025)¶

Date	Insider	Action	Size	Price	Value
2026-06-25	David A. Ricks (Director)	Purchase	10,000	$194.51	$1.95M
2026-07-29	J. Forusz (Officer)	Sale	416	$264.33	$110K
2026-04-30	J. Forusz	Sale	755	$246.24	$186K
2026-04-28	S. Narayen (CEO, indirect)	Sale	75,000	~$243–245	$18.27M
2026-04-20	D. Durn (listed as CFO)	Sale	1,336	$248.02	$331K
2026-01-27	D. Durn	Sale	1,646	$294.85	$485K
2025-10-31	J. Forusz	Sale	149	$337.88	$50K

Totals since October 2025 (derived): sales of about $19.4M, of which the CEO's single sale is 94%, against one purchase of about $1.95M.

Director Ricks bought 10,000 shares at $194.51, about 2% above the 52-week low of $190.12. He also bought 2,250 shares at $443.98 in January 2025, so that earlier purchase is now deeply underwater. At the inferred price his June purchase is about 24% in the money.
The CEO's April sale was near today's inferred price. Sales by Forusz and Durn have been small and regular. The tools don't say whether any were under pre-arranged 10b5-1 plans.
Most other entries are routine. They carry no price or transaction type and cluster on the 15^th and 24^th of Jan/Apr/Jul/Oct, plus a few on the 13^th–15^th of other months. That pattern looks like scheduled vesting or tax withholding, not discretionary trades. Don't read them as signals. More should appear around Oct 15 and Oct 24.
The CFO appears to have changed.
Daniel Durn is labeled CFO through 2026-04-20, and COO on the 2026-04-15 entry.
Steven Day appears as CFO from 2026-06-15.
The labels are inconsistent, so verify this against the company's filings.

7. Takeaways for traders¶

Supportive - Revenue growth is accelerating (12–13%) on a $26B base. - Gross margin is about 89%, and FCF margin is high (36–41%). - Valuation is low (13x GAAP earnings, about 10–11% FCF yield). - The stock is roughly 34% below its 52-week high. - A director bought near the low, and buybacks are cutting the share count by about 7% a year.

Cautionary - Profit growth (+3% net income, +9% operating income) is well below revenue growth. Operating margin is down about 130–150 bps year over year, and cost of revenue growth has accelerated for three straight quarters. - EPS growth depends on buybacks. Cash is down 43% from November 2024, the current ratio is 0.77, and liabilities are rising while equity has shrunk. - The CEO sold $18M of stock in April. Beta is 1.4. The inferred price is below both its 50-day and 200-day averages. - The forward P/E isn't like-for-like with the trailing P/E.

What to watch next - Whether gross and operating margins stabilize in the Q4 FY26 report. I'd expect it around mid-December, based on Adobe's usual schedule, but I haven't confirmed the date. - The 10-Q detail on the $1.9B of nine-month investing outflow, the current-liability growth, and the buyback pace. - Any further insider purchases at current levels, and the CFO transition.

8. Summary table¶

Category	Key point	Reading
Valuation	P/E 13.2 trailing, 8.75 forward; PEG 0.57; P/B 8.0; FCF yield about 10–11%	Cheap on GAAP; forward EPS likely non-GAAP
Price (inferred)	About $240.7; 52-week range $190.12–$363.70; about 6% below the 50- and 200-day averages	Mid-to-lower range, weak trend
Revenue	Q3 FY26 $6.76B, +12.9% YoY; 9-month +12.5%; FY25 $23.77B (+10.5%)	Growth accelerating
Gross margin	89.6% → 89.2% → 88.7% across Q1–Q3 FY26	Slipping as cost of revenue growth accelerates
Operating margin	Q3 34.8% vs 36.3% a year ago; 9-month 35.4% vs 36.7%	Compressing about 130–150 bps
Net income / EPS	Q3 $1.83B (+3.1%), EPS $4.62 (+10.5%); TTM net income $7.28B	EPS aided by about 7% fewer shares
Cash flow	9-month OCF $7.65B (+11%); FCF about $7.47B; TTM FCF $9.35B (vendor) vs about $10.6B (derived)	Strong, and the vendor figure is lower
Capital return	No dividend; 9-month financing outflow $6.81B (about 89% of OCF); FY25 above 100%	Buybacks slowing but still heavy
Liquidity	Cash $4.36B (−43% from Nov-24); current ratio 0.77	Thin, but backed by FCF
Leverage	Debt/equity 57.7% (about $6.8B debt); liabilities $18.2B vs equity $11.8B	Rising, manageable
Returns	ROE 61.9%, ROA 20.1%	ROE inflated by lower equity
Insiders	Sales about $19.4M (CEO $18.3M in April) vs one $1.95M director purchase at $194.51	Mixed, and nothing new in the past week
Management	CFO apparently moved from Durn to Day (Jun-26)	Verify
Data limits	No Q4 quarterly data, YTD cash flow, inferred price, no news or deferred revenue detail	Confirm with filings and a live quote

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for ADBE at $240.68

Since the bear hasn't spoken, I'll make my case and answer the objections I expect.

The thesis¶

The market is pricing ADBE as a business in terminal decline from AI. The reported numbers show a business that is growing faster, generating more cash, and trading at a multiple it last saw near the June lows. When the narrative and the financials diverge this much, I want to own the financials.

1. The disruption hasn't shown up in the numbers¶

If generative AI were cannibalizing Adobe, revenue growth would be decaying. It is doing the opposite:

Revenue growth: +12.0% (Q1), +12.7% (Q2), +12.9% (Q3), up from +10.5% in FY25, on a $26B base.
Operating cash flow is up 11.3% over nine months, and FCF is about $7.5B year to date.
Gross margin is 88.7%, with operating margin around 35%.

A value trap has shrinking revenue and eroding cash flow. ADBE has neither. Even HSBC's note, per the headlines, flags "headline risk" from a free clone, which is a risk to sentiment and not a reported decline in the business.

2. The price already assumes decay¶

Since the 2025 high ($359.91), the stock is down about 33% while revenue growth accelerated. On FY25 EPS of $16.70, that is roughly 21–22x then versus 13.2x GAAP now (derived). That is pure multiple compression.
Market cap is $93.7B against TTM FCF of roughly $9.4B (vendor) to $10.6B (derived), a 10–11% FCF yield for a 35%-operating-margin software franchise.
I won't lean on the 8.75x forward P/E. It likely reflects non-GAAP estimates, so I'm anchoring on the trailing 13x GAAP number. That is already cheap.
Buybacks are shrinking the share count about 7% a year (about 424M to about 395M diluted), so each dollar of buyback retires more of the company at this price.

Even HSBC's downgrade to Hold carries a $267 target, about 11% above today's price. That is a cautious analyst, not a bearish one.

3. The market has already shown it pays up when fear eases¶

In June the stock hit a washout. Volume reached 25.0M on June 12, the highest in the dataset, and the intraday low was $190.12. On June 25, director David Ricks bought 10,000 shares at $194.51 ($1.95M), essentially the closing low of $193.41. The stock then rallied about 51% to $292.79 by August 31.

The pullback since has been orderly. Price held a higher low ($227.00 on 10/7 versus $224.67 on 9/28), RSI and OBV made higher lows to match, and ATR contracted from 11.06 to 8.26. The weekly SuperTrend, the primary tier, is UP with a stop at $206.08, about 17% below. Price also held up through the downgrade, which I infer hit on 10/13, and closed today near its high.

4. Preempting the bear¶

"Margins are compressing." Q3 operating margin was 34.8% versus 36.3% a year ago, a 150 bp decline. But gross margin accounts for only about 60 bps of that (89.3% to 88.7%). The rest is operating spending, which is a choice. A company reinvesting in AI while accelerating growth is the right trade-off. Margins are still elite, and I'll treat them as a risk to monitor, not a reason to ignore the cash flow.

"Net income is up only 3% on 12% revenue growth." Operating income is up about 9% over nine months, and Q3 EPS is up 10.5%. The tools don't break out interest, tax or other income, so I won't pretend to know the gap. But the cash flow statement, where OCF is up 11%, doesn't show the same softness.

"The balance sheet is stretched." The current ratio of 0.77 is normal for subscription software carrying deferred revenue. Debt of about $6.8B is less than one year of FCF. Net debt of about $2.4B is overstated because short-term investments aren't shown, and it is roughly three months of FCF in any case. The 43% cash decline since November 2024 was a choice to return capital, not distress. Financing outflows have already slowed to about 89% of OCF from more than 100% in FY25.

"The CEO sold $18M." That sale was in April at about $243–245, nearly today's price, and the tools can't tell us whether it was part of a pre-arranged plan. Against it stands a director putting $1.95M of fresh cash in near the bottom. The CEO handoff is only a headline reference, and I can't verify the details. A successor with a fresh strategy could be a catalyst, but that is optionality and not part of my thesis.

"Rates and the Fed." This is the bear's best macro point. Polymarket puts a 97% probability on no cuts in 2026 and 82% on another hike. But Adobe's cash flows are recurring and don't depend on rates. Rates hit the multiple, and the multiple is already at 13x. The same markets price only an 8% chance of a US recession.

"Price is below the 50 and 200 SMAs, and the daily and monthly SuperTrends are down." That is true, and I won't call the 50/200 "golden cross" bullish, because the 200 SMA falling toward price caused it. A daily close above about $257 would flip the daily trend and reclaim both averages. Until then I'm using risk controls instead of arguing the chart is better than it is.

5. How I'd frame the trade¶

Risk: a 2×ATR stop at about $224 sits just under the recent swing lows, about 7% below.
Reward: the 255–257 resistance cluster is about 6–7% up, then 265–266 (HSBC's $267 target is nearby), then the August peak at $292.79, about 22% up. That is roughly 3:1 to the August high against a defined stop.
What would change my mind: revenue growth slipping back below about 11% in the December report, gross margin breaking below 88%, a close below about $224, or a weekly SuperTrend flip below $206.

The bottom line¶

I'm not claiming the AI risk is imaginary. I'm saying it is priced in at 13x earnings and a 10%+ FCF yield, while accelerating revenue, growing cash flow, a shrinking share count and insider buying near the low all point the other way. The bear needs the numbers to start breaking soon. So far they haven't.

I'd like to hear the bear's answer to one question: where in the reported financials is the cannibalization, and why does the stock deserve a 13x multiple while that evidence is absent? Bull Analyst: # Bull Rebuttal: ADBE at $240.68

You made some good points. Here is what I concede, then where I think you overreach.

What I concede¶

The June multiple. I said ADBE trades near its June multiple, and that was wrong. Your math ties: $193.41 on TTM EPS of about $17.80 is 10.9x, against 13.2x now. Downside to roughly $200 if the market re-rates to June levels is real.
No floor at 13x. With 97% odds of no cuts and 82% odds of another hike, I won't call 13x a floor.
The higher lows. $2.33 is 0.28 ATR, and the technical report calls it "mild improvement, not a classic divergence." I'm dropping it as evidence of strength. It only shows the lows haven't broken.
June is not today. Volume is thin, RSI is 46.6 and the z-scores are near zero. This is a bounce in a range, not a washout.
Trade math to the first wall. To 255–257 it's about +$16 against −$16.5, so 1:1. I'll restructure the entry below.

1. Cost of revenue: your slope is real, but the base is small¶

Cost of revenue is only about 11% of revenue, so +18.8% growth in it sounds worse than it is. In Q3:

Revenue rose about $772M.
Cost of revenue rose about $123M.
The incremental gross margin was about 84% (derived). That's what a new dollar of revenue earned after delivery costs, and it is still elite.
Gross profit grew about 12%, roughly in line with revenue.

Gross margin is down 60 bps year over year. That deserves attention, but it isn't evidence of a franchise being hollowed out.

On operating margin, FY21–FY25 ran 36.8%, 34.6%, 34.3%, 31.3% and 36.6%, averaging about 34.7%. (FY24 includes a one-time charge that I'm inferring.) The nine-month figure of 35.4% sits at the middle of that range, and Q3's 34.8% was up 100 bps from Q2's 33.8%. The compression is real, but it looks like FY25's peak reverting toward the norm, not a break.

Your counterfactual (10.5% growth at a 36.3% margin gives $2.40B) assumes the margin would have held without the spending that accompanied the growth, which is the very thing in dispute. It also treats $143M of extra recurring quarterly revenue as worthless.

On the revenue lag: if revenue lags, there has to be a limit. The stock has fallen from $360 over roughly a year, and the market has been pricing AI disruption since at least the March 13 gap. If the contract mix is largely annual, a full renewal cycle has already come due since then, and growth accelerated through it. I can't verify the contract mix, but that is the test the bear's own lag argument sets.

2. The net income gap is the bear's best point, and it's unexplained¶

Nine-month operating income rose about $567M, but net income rose only about $153M. Roughly $400M of operating gain disappeared below the line (derived). Possible causes include lower interest income as cash fell, a higher tax rate, or investment losses. The tools can't say which, so I won't claim to know.

Operating cash flow rose 11.3%, and the cash flow statement shows none of the drag that net income does. Gross profit (about +12%) and OCF (+11%) track revenue, while operating income (+9%) and net income (+3%) lag. The lagging lines are the ones that include discretionary spend and non-operating items.

You're right that cash margins aren't expanding. But FCF margin has held around 38% (derived), so it is flat and not eroding. My thesis needs durability, not operating leverage.

3. Valuation: the GAAP multiple already charges for SBC¶

You said the FCF yield is pre-SBC, and that's fair. But that is why I anchor on GAAP earnings. The 13.2x multiple is after stock comp, and its 7.6% earnings yield is the SBC-burdened number. Treat the 10–11% FCF yield as an upper bound if you like, since the 7.6% still stands on its own.

On buybacks, I can't defend what was spent at $350–440. That is sunk, and the director's January 2025 buy at $443.98 is a good example. But the buyback going forward retires shares at a 7.6% earnings yield, against about 4.6% at the $360 high (1 ÷ 21.5x). The same dollars are worth more shareholder value now.

On PEG, 13.2x on 10.5% EPS growth is about 1.3, and I accept that it's not the vendor's 0.57. That is fair for a business with 89% gross margin, though not obviously cheap. The case rests on durability at a market-wide discount, not on growth at a bargain.

4. The balance sheet: "114% of OCF" overstates the burn¶

Your figures tie: financing outflow was $6.81B and investing outflow was $1.91B, against OCF of $7.65B, and cash fell $1.07B. But the investing outflow didn't vanish. Total assets rose $485M over the same period while cash fell $1.07B, so about $1.6B went into non-cash assets (derived). It could be short-term investments or an acquisition, and the 10-Q will say which. Either way, it is reallocation, not burn. Equity is flat to up in 2026 and liabilities rose only $344M. This is a company choosing to return capital, not funding it by borrowing.

5. Trade structure: what I'd change¶

Gap risk. The two worst gaps in the data were −7.6% and −6.8%. From $240.68, a −7.6% day lands near $222.4, about $1.80 below my $224 stop. That would be a roughly 10% overshoot of planned risk, not a blown-up position. These are the worst days in this dataset, not a ceiling.
Entry. I'd scale in. Take a half position now and add on a retest of 228.8–231 (the lower Bollinger band and the Sept 28 closing low), keeping the stop below $224. At a $229 entry, risk is about $5 against about $27 to 256, which is better than 5:1.
Confirmation. Add the rest only on a daily close above $257 with RSI above 50 and above-average volume. That is your own turn-constructive trigger.

Your question: what leading signal would I accept?¶

You're right that revenue below 11% is a lagging trigger. I'm replacing it with these:

Q4 gross margin of 88.2% or lower with cost of revenue growth above 20%. That would be a third straight ~50 bp slide, and I'd cut the position in half.
Q4 operating margin below 33.8%, the Q2 low, with revenue growth of 12% or less.
Q4 revenue growth below 12.0%, which would reverse the three-quarter acceleration.
Disclosure change. If the Q4 report confirms Adobe dropped or reframed ARR or subscription metrics, I treat that as negative whatever the headline numbers show. The "cracks" headlines are unverified, but if you're right about them, this is how I'd find out.
Price. A close below $224, or a weekly SuperTrend flip below $206.

Any one of the first three halves the position. Two together, or the disclosure change, closes it.

Bottom line¶

The bear's case rests on what we can't see: ARR, SBC, the net income gap and whatever Adobe may have stopped disclosing. My case rests on what is reported: 12.9% revenue growth, about 84% incremental gross margin, about 38% FCF margin and a GAAP earnings yield of 7.6%. Neither of us can close the gap until the 10-Q and the December print.

So I'm sizing this as a defined-risk bet on durability at a discount, with no floor claimed at 13x and staged entries. If the next print shows the margin slide continuing, the bear was early and right, and my rules say I leave. Bull Analyst: # Bull Rebuttal: ADBE at $240.68

You closed by asking what protects me from a gap. Nothing in a stop does. Sizing does, and I'll rebuild the position around that in section 5. First, the accounting.

What I concede¶

The incremental margin table. Your arithmetic ties. New Q3 revenue kept 23% at the operating line and 7% at net income. Over nine months it's similar: +$567M of operating income on about +$2.2B of revenue is about 26% (derived). My 84% was real at the gross line, but it isn't what shareholders keep.
The margin norm. My 34.7% average included the FY24 charge. Excluding it, the five-year average is about 35.6%.
The renewal-cycle test. It was weak. Seven months is not a full cycle, and price or packaging could be pulling revenue forward. I withdraw it as evidence either way.
The 5:1. A $5 stop on a stock with an $8.26 ATR is noise, and the adverse-selection point on a limit fill is fair. I withdraw the $229 add-on.
Exit rule #1. A straight-line step of about $49M a quarter in cost of revenue gives a Q4 gross margin of about 88.3%, right on my 88.2% line. It is close to a coin flip at the first print.
Leading indicators. My December triggers all arrive with the print.

1. The margin story is partly reversion, partly reinvestment¶

Nine-month operating margin is 35.4%, against an ex-charge five-year average of 35.6%. The compression is measured against FY25's 36.6%, which was near the top of the 34.3–36.8% range. Quarterly margins also swing a lot (37.8%, 33.8%, 34.8% this year), so one Q3-over-Q3 comparison is thin evidence of a trend. I'd rather weigh the nine-month figure.

I still accept that opex grew 14.7% against revenue growth of 12.9%. Whether that is recurring defense or investment that can be throttled is the December question. A flat gross margin plus opex growth falling below revenue growth would answer it. If Q4 shows neither, I cut.

2. GAAP consistency and the net income gap¶

You're right that I can't anchor on GAAP and then wave off GAAP growth. The consistent version is that P/E is per share, so the matching growth rate is EPS growth, not net income growth. EPS rose 10.5% in Q3. TTM EPS of $18.24 is also 9.2% above FY25's $16.70 after three quarters of turnover (derived). About 7 of those points come from the share count, and I'll own that. It's real ownership transfer, and the funding is visible. Nine-month financing outflow of $6.81B was below nine-month FCF of $7.47B. The extra investing outflow is what drew cash down. A PEG near 1.3 is fair, and I'm not calling it cheap.

On your interest-income theory, I tested it:

Cash fell about $3.3B from Nov-24 ($7.61B to $4.36B).
At a 4–5% yield (my assumption, since the tools give no rate), that is roughly $130–165M a year. Over nine months it is about $100–125M.
The pre-tax gap is about $400M (derived), so lower interest income explains perhaps a quarter to a third of it.

The rest is tax, investment marks or interest expense, and I don't know which.

On OCF, you're right that the bridge isn't itemized. But look at the balance sheet. Current liabilities rose $1.69B while non-current liabilities fell $1.34B. If the rise is deferred revenue, customers are prepaying, which is bullish. If a note moved to current, the size is about $1.3B, roughly two months of FCF against $4.4B of cash. Neither reading is a refinancing problem for a company producing $9–10B a year.

3. The filing is a gate¶

You're right that the Q3 10-Q should be public, and I can't pull it from here. Neither of us has read it. I'll treat it as a gate and hold a starter position until someone checks four things:

The net income bridge.
The current-liability split.
The $1.9B investing outflow.
Whether ARR or subscription metrics were dropped or reframed.

If the fourth is yes, my rule closes the position. I'd note that Trefis's headline is a question, and "the change is already in published reports" is your inference, not a finding. That is why I want it read rather than argued.

4. Valuation without relying on stops¶

Instead of R:R off a tight stop, here are the 12-month prices (derived, illustrative) for TTM EPS of $18.24 at three growth rates and three multiples:

EPS growth	11x (June low)	13.2x (flat)	15x
0%	$201	$241	$274
5%	$211	$253	$287
10%	$221	$265	$301

Your $199 target is the top-left cell, where EPS stalls and the multiple returns to June's. At the current ~10% EPS growth and a flat multiple, the stock is near $265. I also don't need 16x for $293. On 10%-grown EPS it takes 14.6x.

The table has a cost too. At 5% EPS growth and a flat multiple, the return is about 5%, which doesn't pay for the risk. The thesis needs roughly 10% EPS growth, meaning buybacks continue and net income grows at least about 3%. That is exactly what the December print tests.

On why the multiple hasn't re-rated despite accelerating growth, the sector-wide derating and the rate backdrop explain much of it. It also says that growth alone won't re-rate the stock. Durability evidence will, and that is what I'm waiting for.

5. Your question: what protects me from a gap?¶

A stop doesn't. A close-based exit can fill well below $224. Three things do the work:

Size to your downside, not my stop. I risk 1% of the portfolio at $199 (−17.3%), which means a position of about 6%. A −7.6% gap then costs about 0.5% of the portfolio, and a full retest of the June intraday low at $190 (−21%) costs about 1.3%. Under this sizing, a gap on another downgrade is a bad day, not a bad year.
Starter size plus a gate. I add only on confirmation, which is your own constructive trigger: a close above $257 with RSI above 50 and above-average volume, or a clean 10-Q read.
Interim tripwires. Between now and December I would cut half on a second disruption-citing downgrade that comes with estimate cuts. I would do the same on a close below $227 on volume above the roughly 4.2M 10-day average, a break the technical report says gains weight on rising volume.

A put spread is the direct hedge, but the packet has no options data. I can't tell you whether the premium is worth it, so I won't pretend to.

Bottom line¶

You've taken the 13x floor, the June analogy, the higher lows, the 5:1 and the renewal test. What remains is narrow. Is a roughly 10% EPS grower with 88–89% gross margin, a roughly 38% FCF margin, a 7.6% earnings yield and a shrinking share count worth 13x when its one visible stress line, cost of revenue, is growing 19%? I say yes at 6% sizing, with December as the judge.

We already agree on the test. Q4 gross margin at or above 88.7%, disclosure that shows durability and a close above $257 move you toward constructive, and the reverse sets my exits. We disagree only on whether to carry a small position while we wait.

My question for you: you call the margin slide an AI tax, and I call it reinvestment. What observable result would make you reclassify it, and does one exist before the stock has already moved? If the answer is nothing, the bear thesis isn't falsifiable on the same timeline as mine either. Bull Analyst: # Bull Rebuttal: ADBE at $240.68

Your question¶

If Q4 prints at trend, with revenue +13%, gross margin 88.4%, operating margin 34.3%, net income flat and EPS up about 8%, I'm out.

My own thesis said I needed about 10% EPS growth and at least about 3% net income growth. That print misses both. My December tripwires were set where they wouldn't fire on the base case, which was a design flaw. I'm adopting your three rules as written:

Q4 operating margin below 35.0%.
A cost-of-revenue step above $40M, which is gross margin below about 88.5% on $7.0B of revenue.
Incremental operating margin below 20%.

One rule halves the position and two close it. At trend all three fire, so the position closes.

As for what December gates, it's everything past the starter. Above trend I add, at trend I leave, and below trend I leave faster. A gate that releases me in the base case is doing its job, because the information is in the branches where the answer changes the action.

What else I concede¶

Your table math. The equal-weight average is about $250 (+4%), and the 62% break-even on the anchor cells ties. For a 1.4-beta stock that is not a reason to own it at trend.
The EPS base. Four reported quarters sum to about $17.9, not $18.24, so "flat multiple" is 13.4x. My table was about 2% generous.
Q1 FY27 comp. Against 37.8% it is harder on operating margin.

Two corrections that matter¶

1. Q4 FY25 wasn't an outlier on conversion. You said it was last year's best-converting quarter at about 82%, against 77–78% in H1 and Q3. Those 77–78% figures are FY26. FY25 ran about 82% throughout (all derived):

	H1	Q3	Q4
FY25 net income ÷ operating income	~82%	81.5%	82.4%
FY26 net income ÷ operating income	77.3%	77.6%	at trend ~77.5%

Q1 FY26 was 78.1% and Q2 was 76.5%. That looks like a step at the fiscal-year boundary, not a slope. Creeping costs, such as a cash drawdown reducing interest income, would erode gradually. A clean break at the start of the year looks more like an annual tax-rate change or a prior-year item in the base. I can't verify which, because the tools don't show the tax or other-income lines.

If it's a step, the "net income +3%" headline is a one-time level shift that laps in Q1 FY27. From there, net income growth tracks operating income growth. At trend that is roughly 6–8%, from 18–23% incremental margin on about 12% revenue growth. Add a 6–7% share shrink and EPS growth is 13–15% (derived, illustrative). Under a step, the 10% row in my table isn't the shaky one. Under a slope, you're right, and I'm out.

That gives me a test I didn't have before: Q4 conversion at or above about 77% means a step. Below 76% means a slope, and I exit. It's cheap to check, and the 10-Q's tax line may settle it sooner.

2. My interest-income estimate was wrong, in the direction that hurts me. I used the full $3.3B cash drop from Nov-24. The right comparison is the nine-month average balance this year against last year. That is about $1.9B lower, using interpolated Aug-25 cash since the packet doesn't give it. At an assumed 4.5% yield, that is about $60M over nine months, or roughly 15% of the ~$400M gap, not a quarter to a third. So more of the leak is unexplained than either of us agreed last round. That raises the value of reading the filing and is why I'm cutting the starter.

What the payoff math requires¶

I'll use illustrative payoffs: +10% above trend, about +2% at trend (where I'd exit), and −15% below trend (about 11x on $18.3). Break-even needs P(above trend) to be at least about as large as P(below trend), and somewhat larger if you think the bad branch is big. For example, 31% above with 25% below, or 21% above with 20% below.

I don't have an edge in picking between those, and a two-point cost line ($50M, $49M) is thin evidence either way. FY25's within-year cost steps were roughly +15, +5 and −4 (derived, ±$15M noise). So a ≤$35M step isn't exotic, but a ≥$62M step isn't either. The payoffs are negatively skewed, so the pre-print edge is thin. That is why I'm cutting the starter from 6% to 3% until someone reads the net income bridge. I'll go back to 6% only if the filing supports the step reading, or if a daily close above $257 on volume with RSI above 50 arrives first.

The symmetric problem¶

Your constructive triggers (Q4 gross margin ≥88.7%, operating margin ≥35.5%, net income +5%, a close above $257) also arrive with the print or after a roughly 7% move. Waiting for confirmation costs you the same repricing it costs me. And "reduce into 250–257" is also a position, because it sells the above-trend branch. If the two branches are roughly equally likely, trimming there gives away the same convexity I'm paying for with a small starter. The real difference between us is size and who carries the tail.

Bottom line¶

We now agree on the tests, and I've adopted your tighter rules, so the base case closes my position. What remains is narrow. I hold 3%, not 6%, with the gross margin, operating margin and cost-step rules, plus a conversion test that separates a step from a slope. The bear says don't add and trim into resistance.

My question: if the filing shows the net income leak is a step that laps in Q1 FY27, which of your numbers still carries the bear case? Is gross margin sliding about 50 bps a quarter on a franchise with 88% gross margin enough to say 13.4x is too high? Bull Analyst: # Bull Closing: ADBE at $240.68

Short answer: the 3% doesn't earn enough to justify holding it before the filing is read, so I'm dropping the starter.

1. What the 3% earns¶

You're right about the ordering. I called the 10-Q a gate, then proposed carrying risk while I waited at it. But the gate is a few hours of reading, not a December event. Holding through that window with no view on the branch odds is a coin flip with a left tail at least as fat as the right (I'll take your −16.5%). At 3% the whole trade is worth about +0.3% or −0.5% of the portfolio. That is smaller than the error in my own inputs: the EPS base was 2% off, and the cost steps carry ±$15M of noise. I can't defend that on expected value.

The new plan:

Stage	Condition	Position
Now	10-Q unread	0%
Gate	Read moves my odds, not merely "benign"	3%
Confirmation	Daily close above $257, RSI above 50, above-average volume	6%
Q4 print	Rules below	Halve on one, exit on two

The read checks four things: the net income bridge, the current-liability split, what the $1.9B investing outflow was, and whether ARR or subscription metrics were dropped or reframed. A "yes" on the last one means no position. I can't pull the filing in this setup, so someone with EDGAR access should do it before anything else.

2. Exit rules, with your branch added¶

I keep your three rules: Q4 operating margin below 35.0%, a cost-of-revenue step above $40M, and incremental operating margin below 20%. At trend all three fire. I'm also keeping the conversion test: Q4 net income divided by operating income at or above ~77% means a step, and below 76% means a slope, which is an exit.

You flagged a gap: a Q4 that clears every rule but comes with an FY27 guide below FY26. I also recall Adobe guiding with the Q4 report, but that isn't in the packet. Fourth rule: a guide implying lower operating margin than FY26's ~35% (derived), on the same basis, counts as a trigger.

3. What I don't concede¶

The step is already in the price. A step is a lower level and it doesn't come back, as you say. But 13.4x is on post-step TTM EPS, so the level shift costs the multiple nothing further. Only the growth rate matters, and a step means growth normalizes once it laps. If FY25 also carried a one-time benefit, the "21–22x then" was understated and the compression since the high was larger than I claimed. That hurts the earnings-power argument but helps the multiple argument.

"Fallen in each period" is two observations and a forecast. - H1 (27%) and Q3 (23%) are observed. Your 18% for Q4 and 11–15% for Q1 FY27 are straight-line projections. - They assume a $49M cost step, seen twice, and Q3's 14.7% opex growth both persist for five more quarters. - The cost lines are lumpy: steps of about +15, +3 and 0 in FY25, then +24, +50 and +49 in FY26. A series that went from zero to $49M in a year doesn't extrapolate cleanly in either direction. - So "at trend" is my exit reference, not a forecast I give more than even odds. You haven't put a probability on it either, so neither of us has an edge on the branches.

Fair is not sell. You said 13.4x is fair for a ~10% EPS grower. Then the only question is whether EPS growth is 10% or 5%, and the print answers that. I'm not claiming trimming into 250–257 is wrong. It's a coherent risk call if you believe the left tail is fatter. But it sells the above-trend branch before the information arrives, which is the mirror image of buying early. My plan does neither: own it on confirmation and leave on the rules.

A small correction. The 82% is the odds of another hike by Dec 10, not an October-meeting figure, and the packet has no October-meeting odds. Macro is still a headwind, and I'm not disputing that.

4. Where we land¶

Agreed: - Revenue growth is real, and nothing in the packet shows cannibalization in revenue or FCF. - Margin dilution is real: Q3 incremental margin was 23% at the operating line and 7% at net income. - 13.4x is fair for a ~10% grower, not a discount, and 13x is no floor. - The step-versus-slope question is unresolved, and the filing is unread. - The tests are the cost step, operating margin, incremental margin, conversion and disclosure.

Still disputed: - Whether to hold anything before the read. I now say no, so this has largely closed. - Whether a long position trims into 250–257 or waits for the $257 close. - Whether "at trend" is the base case or just the reference line.

Bottom line¶

The bull case is a business with 12.9% growth, ~88.7% gross margin and ~38% FCF margin at a fair price. Its open question is the quality of earnings growth, not valuation, and one filing and one print answer it. I would rather be late and own it on confirmation than hold it on faith. If the read passes and Q4 comes in above trend, the bear's margin-dilution case was early and I add. If Q4 prints at trend or worse, my rules take me out.

Bear Researcher¶

Bear Analyst: # Bear Case for ADBE at $240.68

You closed by asking where the cannibalization shows up in the reported financials. It does show up, just not on the line you're watching. Several of your supporting claims also fail on closer inspection.

1. Where the damage shows up¶

Revenue is the last line to break. Subscription revenue is recognized ratably, so lost renewals, discounting and free-tier substitution reach it with a lag. A franchise under pressure first shows it in cost to serve, margins and profit conversion, and those are the lines that are moving:

Cost of revenue growth went +6.8% → +12.1% → +18.8% across Q1–Q3, against revenue growth of 12.0% → 12.7% → 12.9%. Gross margin went 89.6% → 89.2% → 88.7%. Each incremental dollar costs more to deliver every quarter.
Q3 operating income rose 8.3% on 12.9% revenue growth. Nine-month net income is up 2.9% on 12.5% revenue growth.
The acceleration bought no extra profit. If Q3 had grown at FY25's 10.5% pace at last year's 36.3% margin, operating income would have been about $2.40B. The actual figure was $2.35B. (This is illustrative and derived, and the counterfactual margin is my assumption.)

You call the margin decline "a choice." A choice with no visible return is just a cost. If the AI thesis is right, it isn't discretionary either. It's what defending a franchise against free alternatives looks like, and HSBC specifically flagged headline risk from a free clone.

The metrics that would settle this are ARR, net new ARR, seat counts, renewals and deferred revenue, and none of them are in our data. Two headlines (TheStreet's "cracks," Trefis's "What Is Adobe No Longer Telling You?") hint that disclosure may have changed. They are headlines only and unverified. Still, "the reported numbers show nothing" is a weak argument when the numbers that would show it are the ones we can't see.

2. "Cheap" is weaker than it looks¶

It is not at the June multiple. You said ADBE trades at a multiple it last saw near the June lows. At the $193.41 June close, TTM EPS was about $17.80, so the multiple was about 10.9x (derived by swapping Q3 FY25's $4.18 for Q3 FY26's $4.62). Today's 13.2x is about 21% higher. The market paid 11x for this stock 3.5 months ago under the same narrative. At 11x on today's $18.24, the stock is about $200, roughly 17% below here.

GAAP growth doesn't justify the multiple. 13.2x on 2.9% net income growth is a GAAP PEG of about 4.5, not the vendor's 0.57. Even on buyback-boosted EPS growth of 10.5%, it's about 1.3. You rightly dropped the 8.75x forward P/E, but that was the only route to "cheap on growth." Of the 10.5% Q3 EPS growth, about 7 points are share shrink.

The buyback runs on the balance sheet. - Nine-month financing outflow was $6.81B (89% of OCF). Investing outflow was another $1.91B (25%). - That is 114% of OCF, and cash fell $1.07B over the period. The figures tie (derived). - FY25's $11.06B financing outflow was largely spent with the stock far above today's price. The director's January 2025 purchase was at $443.98. - Equity is down 29% from its peak.

I concede this isn't distress, and a 0.77 current ratio is normal for subscription software. But "slowed to 89%" is still spending more than the company earns once investing is counted, and Polymarket has an 82% chance of another hike.

The FCF yield is pre-SBC. OCF is 1.4x net income, and the tools don't itemize stock-based compensation, so neither of us knows how much of that $2.2B gap is real cost. Nine-month FCF is up about 11% against revenue up 12.5%, so there's no operating leverage in cash either. Treat 10–11% as an upper bound.

3. June is not a template for today¶

June had 25.0M shares of capitulation volume and an insider buying at the low. Today has: - Volume of 3.48M, about 17% below the 10-session average - RSI of 46.6 - Z-scores of −0.03 (weekly) and +0.16 (daily)

Nothing is washed out, and price sits mid-range. Today's close of $240.68 is still below the 10/9 close of $242.27, and the bounce came on thin participation. That isn't resilience.

That 51% rally also gave back 62% in four weeks. The market has been selling rallies in this name.

Your "higher lows" don't carry much weight: - $227.00 versus $224.67 is a $2.33 difference, or 0.28 ATR. - The OBV higher low is about 2%. - The technical report calls it "mild improvement, not a classic divergence" and says there's no accumulation yet. - Two of three SuperTrend tiers are down. The weekly stop at $206 is 14% below the price at which you'd be stopped out.

4. Your trade math¶

The 3:1 holds only to $292.79. To the first real wall at 255–257, where the 200 SMA, 50 SMA and daily SuperTrend stack, it's about +$16.3 against −$16.5. That's 1:1. There are five supply layers between here and August (242–245, 248, 251, 255–257, 266).
Stops don't hold through events. ADBE has had single-day drops of 7.6% (3/13) and 6.8% (6/12). A $224 stop assumes you get filled at $224. Possible catalysts include the late-October FOMC, Adobe MAX, the Nov 3 midterms and the December print. The dates are unverified.
Your own tripwire is close. You said gross margin below 88% would change your mind. It's 88.7% and has slipped 40–50 bps per quarter, which puts the trigger about 1.5 quarters away.

5. Insiders, HSBC, leadership and rates¶

Ricks's purchase was $1.95M, about 0.002% of market cap. His January 2025 buy at $443.98 is down 46%. Against that, the CEO sold $18.3M at about $244, which is 94% of insider sales and roughly today's price. I can't prove it wasn't a 10b5-1 plan, and you can't prove it was.
HSBC downgraded despite a target 11% above the price, and it cited AI disruption, not valuation. The rating carries the conviction and the target is just arithmetic.
Leadership is changing at the top. There is a CEO handoff headline, and the insider labels suggest a CFO change in June. Both are unverified, but a double transition while the market tests the franchise adds risk.
Rates hit the multiple, as you said. But you then argued that the multiple is "already at 13x." June showed the market will pay 11x. With 97% odds of no cuts, 82% odds of another hike, surging global yields and a 1.4 beta, there is no floor at 13x. The 8% recession probability is irrelevant, because the risk here is rates plus AI, not recession.

Where you're right¶

Revenue growth is real. The balance sheet isn't distressed. The weekly trend is up, and trailing valuation is low. I'm not claiming the business is shrinking. I'm saying the return on defending it is falling, and the market is being asked to pay for duration it can't verify.

I'd turn constructive if: - Q4 gross margin holds at or above 88.7% and operating margin recovers above 36%. - Management discloses ARR and net-new metrics that show durability. - A daily close above $257 comes on above-average volume with RSI above 50.

Bottom line¶

You asked for evidence of cannibalization, and I've given it: the cost-of-revenue slope, the 2.9% net income growth, the margin slippage and a buyback-flattered EPS. Your trigger, revenue growth below 11%, is a lagging metric that would likely arrive after the stock has retested $200.

So here's my question for you: what leading metric would you accept as the first sign that the thesis is breaking, given that gross margin is only 70 bps from your own exit? Bear Analyst: # Bear Rebuttal: ADBE at $240.68

You gave up a lot: the June multiple, the 13x floor, the higher lows, "June is not today," and 1:1 to the first wall. I'll treat those as settled. What's left is the part of your case that still doesn't hold.

1. The 84% incremental margin is the wrong margin¶

Your math ties, but gross profit isn't what shareholders keep. Here is the same Q3-over-Q3 comparison all the way down the income statement (derived from the reported margins):

Line	Q3 FY25	Q3 FY26	Change	Share of the new $772M kept
Revenue	5,988	6,760	+772	n/a
Gross profit	5,347	5,996	+649	84%
Operating income	2,173	2,354	+181	23%
Net income	1,772	1,827	+55	7%

84% is below the 89.3% the business earned a year ago, so even your number describes dilution. New dollars are less profitable than old ones.
Total costs grew 15.5% against 12.9% revenue growth. Operating expenses alone grew about 14.7%.
This needs no counterfactual. It's last year's quarter against this year's. The extra revenue is valuable. It just kept about a quarter of what the base business keeps at the operating line.
Your 34.7% "norm" includes the roughly $1B FY24 charge you call one-time. Strip it out and the five-year average is about 35.7% (my inference). Q3's 34.8% is then below the norm, not at it.

2. You can't anchor on GAAP and then dismiss GAAP growth¶

You said you anchor on GAAP earnings because they're SBC-burdened, and I accept that. But you then wave off the 3% net income growth as "discretionary spend and non-operating items." If 13.2x net income is your valuation, then net income growth is your growth rate. That puts the PEG near 4.5, not 1.3. Spending to defend the franchise against free alternatives is recurring, so it doesn't come back out of the cost base.

Operating cash flow isn't independent evidence. The gap between OCF and net income widened from about $1.6B to about $2.2B over nine months (derived). That bridge accounts for roughly 80% of the $775M OCF increase. It could be SBC, D&A, deferred revenue or working capital, and none of it is itemized. If it's SBC, the cash flow growth is being paid for in dilution that the buyback then has to retire. If it's working capital, it can reverse.

You called the ~$400M leak "unexplained," which isn't a small admission. A durability thesis can't carry a gap that size between operating and net income as an unknown. One candidate cause is lower interest income from the cash drawn down for buybacks. That would be a direct cost of the capital-return policy you're defending.

You're also waiting for something that should already exist. The 10-Q for the period ended Aug 28 should already be on file, since the large-accelerated-filer deadline is 40 days, around Oct 7. The tools don't surface it. So "neither of us can close the gap until the 10-Q" is a limit of our tooling, not of the calendar. The right answer to an unread filing is to read it before sizing, not to size around it.

3. The renewal-cycle test fails on its own terms¶

March 13 to today is about seven months. Annual contracts signed after the gap haven't come up yet.
The renewals that did happen came before the free-clone headline and before this week's HSBC call. Those customers renewed without the substitution risk now being priced.
Revenue acceleration is also consistent with price, packaging or credit upsell that pulls revenue forward. The tools can't separate price from volume.
The stock has fallen 33% over three quarters of accelerating growth. The market isn't waiting for revenue to break. If accelerating revenue were the lever, it would have re-rated by now. That leaves you with no identified catalyst.
The acceleration is also flattening: +0.7 points, then +0.2.

4. Your exit rules¶

The gross margin trigger is the base case. Cost of revenue by quarter was about $665M, $715M and $764M, a nearly identical step of about $49M each time (derived). Another step gives about $813M in Q4. On $6.9–7.0B of revenue, that's a gross margin of about 88.2–88.4% and year-over-year cost growth well above your 20% threshold. Your rule says to cut in half in December on a straight line, so the first rule has roughly even odds of firing at the first print.

The gross margin hit is small in dollars, as you said, but it's the one visible place where AI delivery costs would appear. Generative features cost real compute, unlike legacy desktop software. The "free-user bet" headline points the same way, though that's a hypothesis, not a finding.

The disclosure trigger may already be live. You close the position if Adobe dropped or reframed ARR or subscription metrics. Trefis is asking "What Is Adobe No Longer Telling You?" this week, which implies the change is in reports already published, including the September Q3 release. It's headline-only and I can't confirm it. But you wrote the rule, and checking it takes minutes.

None of your replacement signals are leading. Gross margin, operating margin, revenue growth and disclosure all arrive with the print, and so does the gap. Your price rules, a close below $224 or a weekly flip below $206, are the only ones that act between now and mid-December.

5. The 5:1 is an artifact of the stop¶

The stop is too tight. A $229 entry with a $224 stop is $5 of risk, or 0.6 ATR (ATR is $8.26). One ordinary day's range is bigger than that. The 2×ATR logic you used earlier would put the stop near $212.
Gap risk is bigger from the lower entry. A −6.8% to −7.6% gap from $229 lands at about $211.6–213.4. That's a $15.6–17.4 loss against $5 planned, 3–3.5× the intended risk. Your $240.68 example (overshoot of about $1.6, not $1.8) flattered the case.
Adverse selection. A limit order at 229 fills mostly on days when the stock is already falling hard, which is when stops get gapped through.
Blended math. Equal halves at $240.68 and $229 average to about $234.84, with about $10.84 of risk and about $21.16 of reward to $256. That's about 2:1, and only in the scenario where the dip happens. If it doesn't, you hold a half position at about 1:1. Neither case is 5:1.

6. The balance sheet mix¶

Total liabilities rose just $344M, but current liabilities rose $1.69B (10,200 to 11,888) while non-current liabilities fell about $1.34B (derived). If that's deferred revenue growth, it's good. If it's debt reclassified as maturing within a year, it's a refinancing in a market giving 82% odds of another hike. The tools can't say, and the 10-Q would. Your "reallocation, not burn" point on the $1.6B of non-cash assets is fair if those are short-term investments. If they're acquisition goodwill, it's capital deployed at an unknown return.

Where that leaves us¶

Valuation: at 10.9x, the June multiple, TTM EPS of $18.24 gives about $199 (−17%). Reaching 257 requires 14.1x GAAP, and reaching 292.79 requires about 16x. That means multiple expansion into 97% odds of no cuts, 82% odds of a hike and a 1.4 beta.
My stance: I wouldn't add here. If you're long, the 250–257 supply zone is a place to reduce.
What would move me toward constructive: a read of the 10-Q that explains the net income leak, Q4 gross margin holding at or above 88.7%, an ARR disclosure that shows durability, or a daily close above $257 on volume with RSI above 50.

My question for you is this. You've built a position whose rules all fire after the gap, and your price stop covers a normal day, not a 7% event. If the stock gaps on another downgrade or clone headline before December, what in your framework protects you? Bear Analyst: # Bear Rebuttal: ADBE at $240.68

You answered the gap question properly, so I'll start with what I'm giving up.

What I concede¶

Sizing answers the gap. Risking about 1% against a $199 outcome puts a starter near 6%. A −7.6% gap then costs about 0.5% of the portfolio, so "nothing protects you" no longer holds at that size.
EPS is the matching growth rate for a P/E. A PEG near 1.3 is the fair number. My 4.5 used the wrong denominator.
The interest-income test. Lower interest income explains perhaps a quarter to a third of the gap, so my theory was partial. The rest is still unexplained.
A correction to my own math. I said the straight line puts Q4 gross margin at 88.2–88.4%. On roughly $7.0B of revenue it is 88.4%, which is above your 88.2% line. Rule 1 is not a coin flip at trend. It needs the cost step to jump from $49M to about $62M.
Single quarters are noisy. I'll weigh the nine-month figure instead: operating margin of 35.4% versus 36.7% a year ago, down 130 bps. The compression survives that test.

1. Your question: what would make me call it reinvestment?¶

Three numbers from the Q4 print would do it:

A cost-of-revenue step of $25M or less, against $49–50M in each of the last two quarters. On about $7.0B of revenue, that means gross margin of 88.7% or better.
Operating margin of about 35.5% or better. That narrows the gap to last year's Q4 (about 36.4%, derived) from −150 bps to about −90 bps.
Net income growth of 5% or more, meaning the operating-to-net conversion stops falling.

If all three hit, I drop the "AI tax" label and turn constructive. One or two leave me neutral. None of them is the trend line, and I'd call that structural.

Before the print, only the Q3 10-Q is in our packet, and neither of us has read it. Three other leading signals exist in kind but are not in our data: Adobe's pricing, credit and free-tier moves at MAX, estimate revisions after the downgrade, and the traction of the free clone HSBC flagged. So the thesis is falsifiable on December's timeline. The difference between us is who carries risk while we wait.

2. Your tripwires don't fire at trend¶

Here is Q4 if each line simply continues its current slope: revenue +12.9%, a $49M cost step, and opex +14.7%. I backed Q4 FY25 out as annual less nine months. All of it is derived, with about ±$15M of rounding noise on cost.

	Q4 FY25	Q4 FY26 at trend	Your trigger	Fires?
Revenue	~$6.20B	~$7.0B (+12.9%)	growth <12.0%	No
Cost of revenue	~$640M	~$813M (+27%)	>20% and GM ≤88.2%	Growth yes, GM no
Gross margin	~89.7%	~88.4%	≤88.2%	No
Operating expenses	~$3.30B	~$3.79B	none	n/a
Operating income	~$2.26B	~$2.40B (+6%)	none	n/a
Operating margin	~36.4%	~34.3%	<33.8%	No

Your margin trigger is 260 bps below last year's Q4. That is nearly twice the 130–150 bps of compression you have already seen. A fourth straight quarter of erosion at the same slope would not cost you a share. If opex merely matched revenue growth, margin would be about 35.1% and still no rule would fire.
Incremental operating margin is falling. It was about 27% in H1, 23% in Q3 and about 18% at trend in Q4 (derived). Each new dollar of revenue is worth less at the operating line than the last.
Year-over-year gross margin would fall about 130 bps, against 60 bps in Q3.
Q4 FY25 was last year's best-converting quarter. It turned about 82% of operating income into net income, against about 77–78% in H1 and Q3. At trend, Q4 net income is roughly flat to +3%. The next comp is Q1 FY26's 37.8% operating margin, which is harder still.

A tripwire that doesn't fire on the extrapolation of the trend you're worried about is not an exit for that worry. I'd ask for a rule that does fire at trend: Q4 operating margin below 35.0%, or a cost step above $40M, or incremental operating margin below 20%. If you won't set one, December can only teach you something worse than what the nine months already show.

3. Your own table¶

Equal-weight your nine cells and you get about $250, or +4%. That is roughly the 4–5% cash yield you assumed for interest income, for a stock with a 1.4 beta. The weighting is generous, since three cells assume 15x with no named catalyst.
The two anchor cells need about 62% confidence. To break even between $201 (0% growth, 11x) and $265 (10% growth, 13.2x), you need roughly 62% odds on the second, before any return on cash.
The 10% row is the shaky one. Q4 at trend gives EPS growth of about 7–10% with net income flat to +3%, so the growth is nearly all share count again. The row you need is the top of that range. You've already said the 5% row doesn't pay.
A small base check. Reconstructing Q4 FY25 EPS at about $4.45 (derived), the four reported quarters sum to about $17.9, not the vendor's $18.24. The vendor figure is probably TTM net income over the latest share count. That is only about 2%, but "flat multiple" is 13.4x, not 13.2x.

4. Where sizing leaves us¶

Your sizing caps what the position can cost, but it doesn't give a reason to own it. A starter held before the gate means carrying the tail for about +4% expected. If the 10-Q is a gate, read it first and size afterward.

My stance¶

I wouldn't add here. If I were long, I'd reduce into the 250–257 supply zone. I'd turn constructive if Q4 passes the three numbers in section 1, if the 10-Q explains the net income leak, or on a daily close above $257 with RSI above 50 on above-average volume.

My question: if Q4 prints at trend, with revenue +13%, gross margin 88.4%, operating margin 34.3%, net income roughly flat and EPS up about 8%, what do you do? If the answer is "hold," what did the December gate gate? Bear Analyst: # Bear Rebuttal: ADBE at $240.68

You said that at trend you're out. That is the most important thing in this exchange, so I'll start with what I owe you.

What I concede¶

Step, not slope. FY25 converted about 82% of operating income into net income in every quarter (H1 ~82%, Q3 81.5%, Q4 82.4%). FY26 has run 78.1%, 76.5% and 77.6%. That is a level shift at the fiscal-year boundary, and I wrongly framed it as erosion. Your Q4 conversion test is a good, cheap check.
Interest income. Your average-balance estimate, about $60M or 15% of the ~$400M gap, is better than the figure we both accepted last round.
FY25 cost steps were small. My backing-out gives roughly +15, +3 and 0, so a step of $35M or less isn't exotic by last year's standard.
Trimming into 250–257 gives up upside. That is a real cost, not a free action.
You adopted the tighter rules. The base case now closes your position, so the dispute is down to size and holding period.

1. Your closing question: the rules you just adopted answer it¶

You asked which of my numbers still carries the bear case if the leak is a step. Look at your three rules: Q4 operating margin, the cost-of-revenue step, and incremental operating margin. All three sit above the tax and other-income lines. If the filing proves a step, all three still fire at trend. The step reading changes the above-trend branch, where you'd re-add. It can't rescue the position in the base case.

The number that survives is incremental operating margin, which doesn't depend on tax or interest (all derived):

~27% in H1
23% in Q3
~18% in Q4 at trend
~11–15% in Q1 FY27 at trend

The Q1 FY27 figure assumes revenue up 12–12.5%, another ~$49M cost step and Q3's 14.7% opex growth. That gives operating income of about $2.50–2.53B, up 3.5–5% against the 37.8% comp. At 77.5% conversion, net income is up roughly 3–4%. With 6–7% fewer shares, EPS growth is about 10%, not the 13–15% you derived. Your 6–8% net income growth requires incremental margin to hold at 18–23%. It has fallen in each period, so "holds" is an assumption and not an observation.

2. A step is a lower level, not a deferred recovery¶

"Laps in Q1 FY27" means growth stops being dragged. It doesn't bring back the ~4.5 points of operating income that conversion lost. The tools show no tax line, so I can't prove the cause. But the plausible causes of a year-boundary step (a higher effective tax rate, structurally lower other income) are permanent. The alternative, a one-time benefit in the FY25 base, means FY25's $16.70 EPS flattered the "21–22x then" comparison. Either reading lowers earnings power or the baseline we measured against. Interest income explains only ~15% of the gap, so most of it is still unexplained.

3. The payoff math¶

There is no edge, by your own account. With +10%, +2% and −15% payoffs and no view on the branches, the expected value is about zero before the cost of capital. You are carrying a 1.4-beta stock into the late-October FOMC (82% hike odds in the Polymarket data), the Nov 3 midterms and MAX for roughly nothing.
The bad branch is worse than stated. 11x on $18.3 is about $201, which is −16.5%, not −15%. It's a small difference, but it moves the break-even the wrong way.
A stock isn't convex. Your "convexity" is linear exposure with rules that fire after the print. Those rules cut off the at-trend branch (you exit) but not the −16.5% branch, because the gap happens before you can act.
The cost-step history cuts both ways. FY25's sequential steps were about +15, +3 and 0. FY26's are about +24, +50 and +49. A step of $35M or less has happened once in three tries this year, and that was the first.
There's a branch your rules don't cover. Adobe usually gives fiscal-year targets with the Q4 report (my recollection, not in the packet). A Q4 that clears your rules with FY27 targets implying margin below FY26's would fire none of them, and the stock could still reprice. At trend, a conservative guide is plausible.

4. The symmetry argument¶

You're right that waiting for confirmation costs me the same repricing it costs you. But the positions aren't symmetric. I'm not asking anyone to short ADBE. I'm saying pass, and if you're flat, that costs nothing. You'd be holding a position whose expected exit is the base case, for about two months, to own the less likely branch, on which you claim no edge. The 255–257 cluster holds the 200 SMA, 50 SMA and daily SuperTrend, with five supply layers below the August peak. That is where a trim would go.

5. Is 13.4x too high?¶

Not because of gross margin alone. A 50 bp quarterly slide on an 88% gross margin base wouldn't make the case. The case is the combination:

Operating income: incremental operating margin falls every period, so operating income growth decelerates to mid-single digits at trend.
EPS growth: at trend it is mostly the share count.
Rates: 97% odds of no cuts, 82% odds of another hike, a 1.4 beta and surging global yields.
AI risk: HSBC's downgrade this week, citing AI disruption and clone headline risk.

13.4x is a fair price for a ~10% EPS grower, but it isn't a discount. The market paid 10.9x in June, and the stock has re-rated about 23% since without a better operating line. I'm not claiming the stock must fall, only that nothing in the data pays you to hold it before the December print.

Where I land¶

Stance: don't buy here. If long, trim into 250–257.
What flips me constructive:
Q4 cost step of $25M or less (gross margin ≥88.7%)
Q4 operating margin ≥35.5%
Net income growth ≥5%
A 10-Q read that explains the leak
A daily close above $257 on volume with RSI above 50
What we agree on: the tests, and that at trend the answer is no.

My last question: if your own base case is to exit in December and you have no edge on the other branches, what is the 3% earning between now and then that cash isn't? If the answer is "the option on the good branch," that is a trade on a coin flip with a fatter left tail. The disagreement is over whether to own it before the print, not over whether the thesis has been proven. Bear Analyst: # Bear Closing: ADBE at $240.68

You dropped the starter, and I agree with the reason. The gate is a few hours of reading, nobody here has done it, and neither of us has an edge on the branches. That settles the biggest dispute. Below is what I give up, where I still disagree, and where I end up.

What I concede¶

The 82% figure. It's Polymarket's odds of another hike by Dec 10, not an October-meeting number. I tied it to the late-October FOMC, and the packet doesn't support that. The only October-specific evidence is a Bloomberg headline saying hike bets rose, with no magnitude. Macro is still a headwind (97% no cuts, 1.4 beta), but I can't size the FOMC.
The step is mostly in the TTM. TTM includes one pre-step quarter (Q4 FY25, 82.4% conversion). But at trend, Q4 FY26 net income is about $1.86B against about $1.855B a year ago (derived), so TTM EPS barely moves. The level shift adds no new cost to the multiple.
Incremental margin is two observations plus my projections. H1 at about 27% and Q3 at 23% are observed. The 18% for Q4 and 11–15% for Q1 FY27 are straight lines. The direction is evidence, but the later numbers are not.
Fair isn't sell. Trimming is position management, not a claim that the stock is overvalued.

1. My odds¶

You said I never put a probability on "at trend." My judgment is about 55% that at least two of your three rules fire at the Q4 print: - Cost of revenue steps have been about +24, +50 and +49M this year. Two consecutive ~$50M steps are a pattern, not noise. - Opex is growing 14.7% against 12.9% revenue growth, and nothing in the packet suggests spending is about to slow. - Revenue acceleration is flattening (+0.7 points, then +0.2).

Against that, cost lines are lumpy (FY25's steps were +15, +3 and 0). A company with an annual margin target can also throttle Q4 spend, which is a plausible mechanism but not something the packet shows. Using your payoffs (+10% above trend, +2% at trend, −16.5% below) and a 45/30/25 split, the expected return is about +1.0% over two months. The split between the last two branches is a guess.

That is roughly what cash earns, before the 1.4 beta. At 4–5% annual (my assumption, since the packet has no short rate), two months of cash is about 0.8%. I'm not claiming negative expected value. I'm saying it's too thin to carry, which is the conclusion you reached.

2. The 6% add at $257 is the weak link¶

Your first stage, 3% after a clean read, is defensible. The second is not. Compare entry prices against your own table (10% EPS growth at a flat 13.2x gives $265, and the stop is $224):

Entry	Multiple on $18.24	To $265	To $224 stop
$240.68	13.2x	+10.1%	−6.9%
$257	14.1x (14.4x on the $17.9 sum of reported quarters)	+3.1%	−12.8%

Confirmation costs you most of the flat-multiple upside. Reaching the August peak ($292.79) from there needs about 16x. The summer did re-rate this stock from 10.9x to about 16x in two months, so I won't say it can't happen. But the market then gave back 62% of that move, and the re-rating came from the tape, not from earnings. Information is a better reason to add than price is. Your plan should cap at 3% until the Q4 print, which is where the real confirmation arrives.

That also means I need to demote my own trigger. I listed a close above $257 as a reason to turn constructive. At 14.1x it isn't. It means I stop trimming, not that I buy.

3. Trim versus wait¶

You say trimming at 250–257 sells the above-trend branch before the information arrives. The two sides aren't symmetric: - Selling at 250–257 means selling at 13.7–14.1x TTM, against 13.2x now. The extra price comes from the tape, with no new fundamental information. - That zone stacks the 200 SMA, 50 SMA and daily SuperTrend, with more supply layers before the August peak. - If price clears it on volume with RSI above 50, I stop trimming. I'm not selling a breakout.

This only matters for someone already long, and you now hold nothing. So the disagreement is narrow.

4. The guide rule needs a basis¶

Your fourth rule is sound, but "on the same basis" does real work. My recollection is that Adobe's guidance is non-GAAP, and the packet has only GAAP. Our ~35% FY26 operating margin is derived GAAP, so a non-GAAP guide can't be compared against it. The rule only works if someone pulls FY26 non-GAAP actuals and compares the guide with those. The packet also has no consensus, so we can't tell a "conservative" guide from an in-line one.

Where I end up¶

Agreed: - Revenue growth is real, and nothing in the packet shows cannibalization in revenue or FCF. Q2 OCF was −1% year over year, but it sits between +19% and +15% quarters, so I won't argue it. - Q3 incremental margin was 23% at the operating line and 7% at net income. - 13.4x is fair for a ~10% EPS grower, not a discount, and 13x is no floor. The market paid 10.9x in June. - The step-versus-slope question depends on a filing neither of us has read.

Still disputed: - Odds on the Q4 print. I'm at 55% for two or more rules firing, and you won't put a number on it. - Trim versus wait for someone already long. - Whether $257 is a buy trigger. I now say no, and I'd ask you to cap the position at 3% until the print.

My stance: don't buy at $240.68. This isn't a short, because revenue and cash flow aren't breaking. The bear case is quality of earnings (margin dilution, a net-income step of unknown cause), a valuation that is fair but not cheap, a 1.4-beta stock facing a hawkish rate backdrop, and event risk from HSBC's AI-disruption call. The CEO-handoff and "no longer telling you" headlines are unverified, so I'm not counting them as evidence. If long, trim into 250–257.

What flips me constructive: - A 10-Q read that shows the net income leak is a step, with no change to ARR or subscription disclosure. - A Q4 cost step of $25M or less, gross margin at or above 88.7%, operating margin at or above 35.5%, and net income growth of 5% or more.

The first thing to do is have someone with EDGAR access read the Q3 10-Q, because both of our positions depend on it.

Research Manager¶

Recommendation: Underweight

Rationale: This debate converged more than most, so the call comes down to how much the remaining gap is worth. The bull's opening case was strong on what's reported. Revenue growth accelerated (+12.0%, +12.7%, +12.9%), gross margin is ~88.7%, FCF is ~$7.5B year to date, the share count shrinks ~7% a year, and the stock trades at ~13.2x GAAP TTM EPS. Nothing in the packet shows cannibalization in revenue or cash flow, and the bear agreed. That is why this isn't a Sell. But the bull then conceded most of the supporting structure. He conceded the June-multiple comparison: June was 10.9x, so 13x is no floor and ~$200 is a live downside. He conceded the higher lows were noise, June's capitulation isn't today, the 5:1 trade math depended on a stop inside one ATR, and the renewal-cycle test was weak. He also conceded the bear's incremental-margin table: of Q3's extra $772M of revenue, 23% reached operating income and 7% reached net income. Cost-of-revenue growth went 6.8%, 12.1%, 18.8% while opex grew ~14.7% against 12.9% revenue. The decisive exchange was the bear's at-trend Q4 projection: gross margin ~88.4%, operating margin ~34.3%, net income roughly flat and EPS up ~8%, mostly from buybacks. The bull admitted that print fails his own thesis, which needs ~10% EPS growth. He adopted the bear's tighter exit rules, under which all three triggers fire at trend. The bear puts ~55% on two or more rules firing. With the bull's payoffs (+10% above trend, +2% at trend, -16.5% below, ~11x on $18.3), that gives roughly +1% over two months. That is about cash, for a 1.4-beta stock with a negatively skewed payoff, 97% odds of no cuts and 82% odds of another hike by Dec 10, and HSBC's fresh AI-disruption downgrade. The bull ended at a 0% position until the Q3 10-Q is read. Neither side could explain ~85% of the ~$400M operating-to-net-income gap. So both agree not to add here, valuation is fair rather than cheap, and the at-trend base case closes the long thesis. The only real disagreement is whether an existing holder trims into the 250-257 supply zone (200 SMA, 50 SMA, daily SuperTrend) or waits. I side with the bear. Selling at 13.7-14.1x on tape strength with no new information, ahead of a print whose more likely outcome breaks the bull thesis, is better risk management than carrying full weight. The bear also showed that buying the $257 breakout at ~14.1x leaves only ~3% to the flat-multiple $265 target against ~13% to the $224 stop. Conviction is moderate, not strong: revenue and FCF are intact and the bear explicitly isn't short, so this is a trim and not an exit. Missing evidence the trader should know about: the Q3 10-Q (net income bridge, current-liability split, the $1.9B investing outflow, any change to ARR or subscription disclosure), the SBC breakdown, consensus estimates, options pricing and confirmed event dates (Adobe MAX, the December print, the CEO-handoff details) are all absent from the packet.

Strategic Actions: 1) No new buying at $240.68 and no chasing a breakout. A daily close above $257 on above-average volume with RSI above 50 means stop trimming, not buy, because it is ~14.1x TTM. 2) For existing holders, cut to roughly 50-60% of a standard allocation, preferably into strength. Work scaled limit orders: about a third of the trim at $248-251 and the rest at $255-257. If price instead closes below $227 on volume above the ~4.2M 10-day average, complete the trim at market. 3) Size the remaining position so a gap to ~$200 (11x, about -17%) or the June intraday low near $190 (about -21%) costs no more than about 1% of the portfolio. Do not rely on stops, given prior single-day drops of 7.6% and 6.8%. Treat a weekly SuperTrend flip (stop ~$206) as the hard exit for any residual. 4) Before taking any further position action beyond the trim, have someone with EDGAR access read the Q3 10-Q for four things: the net income bridge (step vs slope), the $1.69B current-liability increase (deferred revenue vs debt reclassified as current), the $1.9B investing outflow, and whether ARR or subscription metrics were dropped or reframed. A disclosure change means reducing toward 0-25% of standard. A clean read showing a year-boundary tax or other-income step allows restoring to standard weight, but not above it, before the print. 5) At the Q4 print, these are the triggers: operating margin below 35.0%; a cost-of-revenue step above $40M (gross margin below ~88.5% on ~$7.0B revenue); incremental operating margin below 20%; net income divided by operating income below 76%; or an FY27 guide implying lower operating margin than FY26 on a like-for-like non-GAAP basis. One trigger means holding at the reduced weight or trimming further. Two or more means exiting to near zero. 6) Upgrade path to standard weight, and Overweight if price confirms: Q4 cost step of $25M or less with gross margin of 88.7% or better, operating margin of 35.5% or better, and net income growth of 5% or more. 7) A second disruption-citing downgrade that comes with estimate cuts before December means cutting the remaining position in half. 8) No short position, because revenue and FCF are not breaking. Revisit any put-spread hedge only once options data is available, since the packet has none.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan calls for Underweight, which maps to a Sell executed as a trim rather than a full exit. Revenue growth and FCF are intact, but only 23% of Q3's incremental revenue reached operating income and the at-trend Q4 projection (EPS up ~8%, mostly from buybacks) fails the bull's ~10% EPS growth requirement. The technicals support trimming into strength: ADBE is at 240.68, about 6% below the 50 SMA (257.00) and 200 SMA (255.26), which sit with the daily SuperTrend stop (256.93) as a 255-257 resistance cluster. The bounce came on light volume (3.48M vs ~4.2M 10-day average), and the daily and monthly trends are still down. At ~13.7-14.1x TTM EPS a breakout buy leaves little upside, and a flat-multiple target near 265 is only ~3% above 257. Conviction is moderate because there is no evidence of revenue or cash-flow breakage, and the Q3 10-Q, consensus, and options data are missing.

Entry Price: 250.0

Stop Loss: 227.0

Position Sizing: Existing holders: cut to roughly 50-60% of a standard allocation, with about a third of the trim at 248-251 and the rest at 255-257. If ADBE closes below 227 on volume above ~4.2M, complete the trim at market. Size the residual so a gap to ~200 costs no more than ~1% of the portfolio, and treat a weekly SuperTrend flip (stop ~206) as the hard exit. No new buying and no short. If you hold nothing, do not initiate.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Since neither of you has spoken yet, I'll set the terms and answer the objections I expect.

The easy, popular trade here is buying the dip. ADBE is about 33% off its October high, trades at 13x GAAP earnings with a 10-11% free cash flow yield, and StockTwits is tagging bullish. The bolder call is to act on what's in the numbers before confirmation arrives. In Q3, revenue grew about $772M year over year and operating income grew about $181M. Only 23 cents of each new revenue dollar reached operating income, at a company that runs 35% margins. Gross margin has slipped from 89.6 to 89.2 to 88.7 across three quarters, and cost of revenue growth has accelerated from 6.8% to 12.1% to 18.8%. We don't know why. AI delivery cost is a hypothesis, not a finding. But the direction matches the bear thesis: growth that is getting more expensive to produce. Net income grew 3%, and EPS grew 10.5% mostly because the share count fell about 7%. Buybacks are carrying the headline.

To the "it's cheap" crowd: the sub-10x and 8.75x figures are forward and likely non-GAAP. On GAAP numbers it's 13 to 14x, and a low multiple isn't a floor in a sector where estimates are being questioned. The macro also works against software multiples. Polymarket has a 97% chance of no cuts this year and 82% on another hike, and hot inflation is pushing yields up. With a beta of 1.4, that is a poor backdrop for paying up for a 3% net income grower. A flat-multiple target near 265 is only about 3% above the 257 resistance cluster, so the upside for a breakout buy is thin.

On the technicals, the bounce is real but unconvincing. Today's 3.48M shares compares with a 4.2M ten-day average, while the breaks down came on 17M and 25M. Sellers showed up with conviction, and buyers haven't yet. OBV is still near its lows, and the 50/200 "golden cross" is cosmetic, because the 200 SMA fell into price while the 50 is rolling over. Price is 6% below both averages, and the daily SuperTrend stop sits right in that cluster. Selling a third at 248-251 and the rest at 255-257 means selling into a stack of resistance, not panicking at the low.

I'll rebut the neutral view first, since I expect "it's range-bound, weekly trend is up, just hold." The range is roughly 228 to 250, and holding a full position through the middle of it earns nothing for the risk. Selling at the top of the range is better risk-reward. From 250, the stop at 227 is about 9% away, the weekly SuperTrend at 206 is about 18% away, and the realistic upside to 265 is about 6%, through resistance. That isn't lopsided, which is why I call it a trim and not a thesis. I'm also not ignoring the weekly uptrend. Keeping 50-60% of a standard allocation is how we respect it. The residual is our call option on a daily flip above 257, and we hold it with the weekly stop at 206 as the hard exit.

To the conservative view, I expect "exit entirely, the balance sheet is thin and the Fed is hawkish." I disagree. Revenue growth is accelerating to nearly 13%, FCF margins are around 36-41%, and the 0.77 current ratio is normal for a subscription business throwing off roughly $10B a year. Nothing in the data shows revenue or cash flow breaking. A director also bought $1.95M at $194.51 in June. That buy came about 20% below today's price, so it doesn't tell us much about 240, but it argues against treating this as broken. A full exit or a short would be a bet on a break that the evidence doesn't show. The CEO's $18M sale in April, near today's price, is a mild yellow flag and nothing more.

What does the trim cost if we're wrong? If the daily SuperTrend flips and the stock runs back toward the August peak near 293, we give up roughly 15% on the slice we sold. I accept that. The sizing rule caps the residual so a gap to 200 costs about 1% of the portfolio, which works out to a position of roughly 5 to 6% of the book. We keep real upside, we put a hard number on the downside, and the proceeds go to opportunities with better asymmetry.

I also want to be honest about the gaps. We don't have the Q3 10-Q, consensus numbers, or options data. That's why conviction is moderate and why the plan is a trim with defined triggers. If ADBE closes above 257 on volume with RSI above 50, the facts change and I'd revisit the plan. If it closes below 227 on volume above 4.2M, we finish the trim at market. Until then, selling into the bounce on rising incremental costs and a thin-volume rally is the right call.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: You two ended up closer to my plan than your opening lines suggest, so I'll say where you moved me and then where I'm holding.

Where you're right

Conservative, the 255-257 limit orders were a hope. My own trigger says a close above 257 with RSI over 50 changes the facts, so Neutral's framing is more coherent: treat that cluster as a test. Sell on a rejection back under 250 and rebuild on a confirmed close above. I'm adopting that.

I'm also dropping "call option." A call has a capped loss and my residual doesn't. 206 is a catastrophe backstop. The residual's real exits are the ones Neutral laid out, about 40% on a volume close under 227 and a quarter or less under 224.67. That makes the 227 trigger the first cut, not the last step of the trim.

Conservative's cost arithmetic checks. Of the 23 cents that reach operating income per new revenue dollar, about 16 cents of the missing 77 is cost of revenue and about 61 cents is operating expense, which grew roughly 15% against 12.9% revenue growth. AI delivery explains under half of the problem.

Neutral is also right that operating expense is discretionary. If December shows opex growth converging toward revenue growth, 23 cents becomes 35 and my thesis is wrong. That is what I'm watching.

Three smaller concessions: - Net income at +3% was the framing that suited me. Operating income is +8% and nine-month free cash flow is +11%. Both still trail revenue, but neither is "a 3% grower." - Today's volume is 17% under average, which is soft, not thin. I'll call the bounce unconfirmed, not unconvincing. - The 10-Q is public. Its absence from my data is a tool gap, not a reason to size down, so I'd read it before the second tranche. - I named no better-asymmetry idea for the proceeds, so they default to cash or short paper.

Where I hold, against Conservative

Selling a big block at 240.68 gives away the middle of the range. The stock just absorbed a downgrade, a hot inflation week and a $236 close, and held 231 to 242. Here's the odds math. 250 is 3.9% away and 227 is 5.7% away, so in a flat range the stock is about 60/40 to tag 250 first. That makes waiting versus selling now roughly a wash in expectation. The edge isn't in timing, it's in conviction, and mine is moderate. That justifies a modest early tranche, not a large one.

"If it rolls over we've sold nothing" is true, but the cost is bounded at about 5.7% to the 227 trigger on the unsold slice. The 14-18% to 206 only applies to what's left after the trim is complete.

Sizing the residual to 2-2.5% so that a trip to 190 costs half a percent double-counts, because that loss is what the exits at 224-227 exist to prevent. Neutral has this right: fix the exit, don't shrink the position. Whether the loss budget is 0.5% or 1% is the caller's choice, and Neutral's stress test (residual weight times about 20%) lets them pick.

Neutral's point also cuts against a heavy sale now. A stock that rose 51% in two months can do it again on a daily flip. If we're down to 25% at 240, we own nothing in that case.

Where I hold, against Neutral

I'd make the first rung smaller. Going to about 85-90% in the 242-246 zone is insurance, and 75% overpays for it. The real sale zone is 248-251. It sits at the upper Bollinger band (250.74), about one ATR away, and just above the 248.3 tag from October 1. Go to roughly 60% there, then about 50% on a rejection at 255-257.

I'd also add one rule you didn't. If the position is still above about 60% as the December print approaches (expected mid-December, unconfirmed), sell down to 60% before the report. The two big-volume breaks in the data look like earnings reactions, as Neutral says. If so, the market has sold off on exactly the margin story I'm worried about. A thesis that says costs are outrunning revenue shouldn't go into a print at full size.

Macro and valuation

You're both right that 97% no cuts is priced in. I'm not selling on the Fed. I'm selling on incremental margins, and I'd use beta only through the stress formula.

On valuation, 13x GAAP with roughly 8% free cash flow yield after a stock comp haircut isn't expensive. But a cheap multiple isn't a catalyst either. HSBC's Hold carries a $267 target, 11% above here, so the street hasn't capitulated yet. If targets get cut toward the price, that's a headwind, though that's my inference.

The bold part of this call was never the size of the trim. It's selling what the crowd calls cheap while it's holding up, because the cost structure says growth is getting more expensive. The retail bull case is seven labeled bulls against two, from five authors, mostly echoing the "under 10x" headlines, which are forward and probably non-GAAP.

The plan, in percent of a full position

242-246: about 85-90%.
248-251: about 60%.
Rejection at 255-257: about 50%.
Close above 257 with RSI over 50 and better volume: hold, and consider rebuilding.
Volume close below 227: about 40%.
Close below 224.67: a quarter or less, with the weekly 206 as the last line.
Sized for the December print: 60% or less going in.

If you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Neutral did the most useful thing in this debate, which was to price the disagreement. I reran it and it holds. On a twenty-point slice, selling at 240.68 instead of 250 costs about three-quarters of a point if the stock rallies, and saves a bit over a point if 227 breaks first. At 60/40 that nets to nothing. So I'm done fighting over the first rung, and I'll say where I'm moving and where I'm still holding.

Conservative, you caught a real contradiction. I said that at 25% we'd own nothing if the stock ran again, but my own rule rebuilds above 257. Buying back at 258 after selling at 240 costs about 7% on the slice. That's a bounded price, and I shouldn't have called it a disaster. You're also right that a limit resting at 242-246 is a hope, because the stock hasn't closed above 242.27 since the September low. So I'll sell about ten points now and ten more into 244-246, which gets us to roughly 80.

You're right on the 227 and 224.67 cuts as well. They're 2.33 apart and fire together on any gap, so it's one cut, to about 30. The table shows nothing between 224.67 and 206, and that air pocket is why it should be one decisive cut. Your "226 close, 219 open" scenario is a procedure problem, not a sizing problem. A close-based trigger doesn't have to wait for the next morning. If the stock is under 227 on heavy volume in the last fifteen minutes, sell then. A heavy-volume trade through 224.67 is also a sale no matter where it closes.

Neutral is right that I can't call December a test of my thesis and then carry 60% into it. I'm coming down to 50.

Here is where I'm holding. On variance as a tiebreaker, Neutral's answer works for me. Variance is always lowest in cash, so it can't decide how much to hold. We've already spent most of the variance budget by agreeing to carry 40 to 50 fewer points than a full position. As for 40 versus 50 into the print, that's ten points times a roughly 7% gap, under a point. The gap can also go up, since a 13x GAAP stock that shows opex growth converging toward revenue growth won't gap down. I'll tie that last ten points to the 10-Q, which brings me to Neutral's best point.

Neutral, the $126M between operating income and net income is bigger than the gross margin story. Operating income grew $181M and net income grew $55M. Falling interest income explains only part of it, since cash is down about $3B from November 2024 and at plausible yields that's tens of millions a quarter, not $126M. It also means I shouldn't lean on "net income +3%" at all. My thesis lives on the operating line, where only 23 cents of each new revenue dollar arrived in Q3 and about 26 cents over nine months.

Here's something I checked that nobody has raised. The nine-month cash walk ties out: operating cash flow of 7,646, less investing of 1,910, less financing of 6,810, is about −1,074, against a reported cash change of −1,072. So the $1.9B investing outflow is real cash going out the door. From memory, and unverified because our data doesn't say, Adobe announced a cash acquisition of Semrush for about $1.9B in late 2025. If that closed in the first half, it could explain a lot of what we've called unexplained. It would account for gross margin slipping each quarter, cost of revenue growth accelerating, opex outrunning revenue, lower interest income, and part of the "accelerating" revenue being bought, not organic.

That cuts both ways. If it's an acquisition, my "costs are outrunning revenue" story is weaker, and so is the bulls' "growth is accelerating" story. This is why conviction stays moderate, and why the 10-Q read happens before the second rung, not after. If the squeeze is acquisition noise, I hold 50 into December. If it's organic, I go to 40 and Conservative gets his number.

I'm still not selling on macro. The hike market is $0.78M deep and I wouldn't size anything off a five-point move in it. I'll run the stress test, residual weight times about 20%, before each event: the late-October FOMC once the date is confirmed, the November 3 midterms, and the print.

In percent of a full position, the plan is this. Sell ten now, then ten more into 244-246, to about 80. Go to 60 at 248-251. On a rejection back under 250 after tagging 255-257, go to 50. A close above 257 with RSI over 50 and better volume means hold and rebuild in steps, but only toward 75-80, because the monthly trend is still down. One cut to about 30 on a heavy-volume close under 227, or a heavy-volume trade through 224.67, with the weekly 206 as the last line for a small core. Go into December at 50, or 40 if the filing says the squeeze is organic. Proceeds sit in cash or short paper until someone names a better idea. If you hold nothing, don't initiate.

This is still the aggressive call. The crowd is buying a "cheap" stock, and we're committing to a specific falsifier, opex growth converging in December, while keeping real exposure to a daily trend flip.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Neutral, Conservative, we've converged enough that I'd rather list what's settled and then argue the three things that aren't. Settled: sell ten now, ten more into 244 to 246, go to sixty at 248 to 251 and about forty-five on a rejection at 255 to 257, make one cut to about thirty on a break, go into December at fifty or less, hold proceeds in cash, and don't initiate if you hold nothing. Those are Neutral's numbers and nearly mine, and the gap to Conservative's is about a point of position value.

Conservative first. You're right that percent of a full position isn't a risk number, and the trader's plan already contains your formula. It says to size the residual so a gap to about 200 costs one percent of the book. That's a 17 percent move from here, which is where the five-to-six percent of the book came from. So I take your override as written: residual weight times the shock, checked against the loss limit, and the lower number wins. Neutral's two shocks work for me, about 20 percent for a slide through the exits and about 12 percent for a print. At a one percent limit, that allows roughly 5 percent of the book going through the exits and 8 percent going into the report. Run it before the FOMC, the midterms and the print, and cut only if it fails. I wouldn't cut pre-emptively for events where my thesis has nothing scheduled to resolve. It resolves in December, and everything before that is price.

You also made the best point about the ladder: it sells strength, and the risk sits in the branch with no strength. That's why I'm selling ten now instead of leaving it all to resting orders. Beyond that, Neutral priced the first rung at about half a point either way, and I'm not going to fight over it.

On Semrush, let me put numbers on how it cuts. If the deal adds a few hundred million a year in revenue, that's $75 to $100 million a quarter, or roughly 1.1 to 1.5 points on a $6.76 billion quarter. If it was in for most of Q2 and Q3, organic growth in Q3 would be near 11.5 percent, below Q1's 12.0 percent. Neutral is right that Q1 already beat last year's 10.5 percent before any deal, but the reading would then be no further acceleration and maybe a dip. That's the number to pull from the filing. I agree with reading it today, not before the second rung. It moves the December weight, not today's trade.

Neutral, three things. On the close-based trigger with no volume filter, I'll take it, and it's safer than I feared. The lowest close of the whole consolidation is 231.01, so a close below 227 is a new closing low by 1.7 percent. September 28's wick, which printed 224.67 and closed at 231.01, never trips it. But your backstop just under 224 sits 67 cents below that same wick, less than a tenth of an ATR. A wick one point deeper sells the low, and then the stock closes back above 230. That order exists only for the day with no close to act on, so I'd put it about a third of an ATR under the swing low, around 222.

On rebuilding, a daily SuperTrend flip plus a close above both averages is the right trigger. Thanks for catching September 14: 265.6 was under the 200 SMA at 266.34, so that rule would not have fired, and it wouldn't have bought the failure. Where I part ways is waiting for a retest before buying anything. The summer move was 193 to 293 in about two months, and V-shaped moves don't always hand out retests. I'd buy the first third on the flip-close, the second on a retest that holds, and the third on weekly follow-through, capped at 75 to 80. A failed first third costs about a point of position value. Missing the first leg of a 50 percent move costs more. Reset the levels weekly, since the 200 SMA is drifting down into the second rung.

On December, you're right that my falsifier was too narrow. Opex growth converging is necessary but not sufficient. If the guide comes with the report, as you recall but haven't confirmed, I want opex converging and a guide that doesn't price in another year of margin compression. Otherwise I'm wrong in one direction and still lose in the other.

This is still the bold call. The retail tape is tagging a 13x stock bullish right after a downgrade, and the numbers say cheapness isn't a catalyst when only 23 cents of each new revenue dollar reaches operating income. We're selling into a thin-volume bounce against that crowd without waiting for estimates to break. But we do it with a named falsifier, mechanical exits and a rebuild trigger, so if the daily trend flips we're back in size. What we give up if wrong is bounded at a point or two of position value. What we avoid is a 17 to 20 percent slide through a thin stretch of the chart between 224.67 and 206, on a stock that has already shown two 7 percent single-day breaks.

Here's the plan in percent of a full position. Every number is a ceiling, so if you're already below a rung you neither sell more nor buy.

Sell about ten now and ten more into 244 to 246, landing at 75 to 80. Go to about 60 at 248 to 251. Go to about 45 on a rejection back under 250 after a test of 255 to 257. Make one cut to about 30 on a close below 227 with a market-on-close order, or on a trade through about 222 as the backstop. Rebuild in thirds as described, capped at 75 to 80. Go into the December report at 50 or less, or 40 if the 10-Q says the squeeze is organic or the loss formula doesn't clear. Run the residual-weight stress before the FOMC once the date is confirmed, before November 3, and before the print. Proceeds stay in cash or short paper, because I still haven't named a better use. I don't know the caller's book, so the loss-limit formula decides the final number. If you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Most of the plan is settled. All three of us sell about ten points now and ten more into 244 to 246. We go to 60 at 248 to 251 and to about 45 on a rejection at 255 to 257. One cut to about 30 comes on a sub-227 close at the 3:50 check, with a stop-market near 222 behind it. We rebuild in thirds capped at 75 to 80, go into December at 50 or less, and don't initiate if you hold nothing. What's left is a few arguments about how much insurance to buy, so I'll take them in turn.

Neutral, you're right on two things. First, I priced this as a point or two of position value, and that was only the first rung. If the stock runs straight to 293, the whole ladder misses about five points after the rebuild claws some back, and the break branch costs about the same. It isn't a cheap option and I shouldn't have sold it as one. Second, selling after a downgrade into down daily and monthly trends goes with the news flow. What I'm leaning against is the valuation crowd: seven-to-two tags from five authors repeating the under-10x headline. That's too thin to borrow confidence from. Mine comes from 23 cents of incremental margin, a cost of revenue line that has accelerated three quarters running, and a named December falsifier, and it's moderate.

Conservative, you said that when the exits work the two branches cost the same, so the asymmetry lives in the gap case and argues for carrying less. I agree the tail is the point. But the loss-limit formula caps exactly that tail, and you've accepted it as the override. If a gap to 200 costs no more than 1% of the book at the weight the caller holds, the tail is already priced in dollars they chose. A lower December number, a heavier print shock and extra selling mid-range are a second premium on bounded risk.

I'll take your best point, though. The formula has to run on the weight held today, not the residual. The ladder sells strength, so in the straight-down branch you're still at 85 or 90 when things break. If that weight fails the test, sell to the passing weight today at market and don't wait for 246. I won't add a number on top of the caller's own limit.

On print stress, I'll take 15%, because it costs nothing. A 1% limit against a 17% move to 200 allows about 5.9% of the book, and against 15% it allows 6.7%. The standing test binds first, so the print number never gets used. The exit budget is similar: 225 if someone is there at 3:50, 222 if not. I'd add one operational rule. Write both orders as "sell down to 30," not "sell 30 points," and cancel one when the other fires. Otherwise a stop that fills at 222 and a close order an hour later can sell the same slice twice.

On the rebuild, your 3% to 266 against 6% of risk is fair for the first resistance level. But the first third is about ten points, so a failure costs roughly 0.6 of a point and a run from 258 back to 293 earns about 1.3. The break-even hit rate is around 30%. You're also right that the summer V began with a record-volume washout near 190, and a flip from here won't have that. So the first third is a probe and the real money goes in on the hold. Skipping the probe entirely risks missing the first leg of a move that was 51% last time, and that costs more than 0.6 of a point.

On proceeds, I side with Neutral. The rule is not to recreate the factor, so the money shouldn't go into another high-beta, long-duration software name. But cash is a default, not a destination. If a caller can't say where the freed risk budget goes within a few weeks, they should recognize this was only risk reduction.

Last, read the 10-Q today. It's the cheapest information we have, and it answers three things. What was the $1.9B outflow? What sits in the roughly $126M between operating income growth and net income growth? And when did the Q3 report land? If it came in mid-September, as Adobe's calendar usually suggests but I haven't confirmed, then the slide from 293 to 231 already contains a reaction to this margin story. That shrinks what we gain by being right, which is another reason to trim and not exit. If the squeeze is acquisition noise, December can be 50 and the rebuild cap 80. If it's organic, December goes to 40.

So the plan, in percent of a full position, with every number a ceiling:

Sell about ten now and ten more into 244 to 246, landing at 75 to 80.
Go to 60 at 248 to 251.
Go to about 45 on a rejection under 250 after a test of 255 to 257.
Make one cut to about 30 on a sub-227 close at the 3:50 check, with a stop-market near 222 behind it.
Rebuild in thirds, capped at 75 to 80, with levels reset weekly. The probe comes on a daily flip with a close above both averages, the next third on a hold, and the last on weekly follow-through.
Go into December at 50 or less, or 40 if the filing says the squeeze is organic.
Run the formula on the weight actually held before the FOMC once the date is confirmed, before November 3 and before the print, and take the smaller number.
If you hold nothing, don't initiate.

The bold part of this call was never the direction. We're acting on a falsifiable thesis, staying in the stock while the weekly trend is up, and committing to buy back on a flip. The cost if we're wrong is a few points of position value, and the formula caps the tail at a number the caller picks.

FINAL TRANSACTION PROPOSAL: SELL

Conservative Analyst¶

Conservative Analyst: I agree with a fair amount of what you said. Trimming is right, a short isn't supported, and I'm not asking for a full exit, because nothing in the statements shows revenue or cash flow breaking. But your own analysis argues for a bigger and faster reduction than the plan delivers.

Start with execution. The plan sells a third of the trim at 248 to 251 and the rest at 255 to 257, and we're at 240.68. Those limit orders only fill after rallies of 3% and then 6%, and you described that zone as a stack of resistance on a bounce with light volume. The resistance that makes it a good place to sell also makes it a poor place to count on. The highest close since the late-September low is 242.27. If the stock rolls over from here, we've sold almost nothing, and the first real action is completing the trim at market under 227 in a falling tape. I'd sell a meaningful chunk now or into 242 to 245 and use the higher levels for the remainder.

The residual isn't a call option either. A call has a small, known premium. You're keeping 50 to 60 percent of a normal position with a hard exit at 206, which is 14% below today's price and nearly 18% below your 250 sale level. By your own figures from 250, that's 6% to 265, 9% to the stop, and 18% to the hard exit. That is negative skew on the part you're keeping, and if it isn't compelling enough for a full position, I don't see why it justifies more than half.

That 206 level also isn't as hard as it sounds. It's a weekly SuperTrend, so it triggers on a weekly close, and this stock has fallen from 269.78 to 249.32 in one session on 17M shares, and from 218.80 to 204.02 on 25M. The June intraday low was 190.12. Sizing for a gap to 200 prices in a level the stock has already traded through. If I size the residual so a trip back to 190 costs about half a percent of the portfolio, that's roughly 2 to 2.5% of the book, not 5 to 6. The weekly signal is also the slowest one on the page. It won't flip until the stock is down 14%, so using it as the exit means taking the loss before the signal acts.

The 227 trigger should also do more than finish the trim. 227 is the higher low, 224.67 is the swing low, and the 2×ATR stop is 224.2. A volume close below that breaks the structure, and I'd cut most or all of the residual there. With a beta of 1.4, a 5% market drop is about 7% on ADBE, which lands near 224. The Fed meeting I believe is in late October needs a date check, and Polymarket has 97% no cuts and 82% another hike. That second market is thin, but the direction is clear.

On fundamentals, I'd refine your cost story. By my arithmetic from rounded margins, of the 77 cents per new revenue dollar that doesn't reach operating income, only about 16 cents is cost of revenue. About 61 cents is operating expense, which grew roughly 15% against revenue at 12.9%. Gross margin explains only about 60 of the 150 basis points of operating margin compression. So the spending issue is wider than AI delivery costs, and we can't see why. Add the unexplained $1.9B nine-month investing outflow and the missing 10-Q and consensus numbers. To me those gaps argue for carrying less, not half.

On "cheap," the 10 to 11% FCF yield is before stock-based compensation, which this data doesn't itemize. Operating cash flow is 1.4 times net income, and I can't tell how much of that gap is real owner earnings. A 13x GAAP multiple on 3% net income growth has no floor. Eleven times TTM EPS of 18.24 is about 200 with no change in earnings. I agree the 0.77 current ratio isn't alarming alone, but cash is down 43% since November 2024, current liabilities are up 29% against 13% revenue growth, and financing outflows are still 89% of operating cash flow. It's manageable, but it isn't a cushion.

On insiders, the director bought at 194.51, 24% below today's price, and his January 2025 buy at 443.98 is deeply underwater. Neither tells us about 240. The CEO sold $18M near today's price, and there are unverified headlines about a CEO handoff and what looks like a CFO change.

Finally, the cost of being wrong isn't symmetric. Missing 15% on the sold slice is an opportunity cost, it's bounded, and we can buy back on your own confirmation of a close above 257 with RSI above 50. Being wrong the other way is a realized loss on a bigger position. Proceeds should sit in cash or short paper unless the better-asymmetry ideas are named.

To whoever argues for holding it all: the range floor at 228 to 227 is the only thing protecting that position, and nothing in the volume or macro data defends it.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: You've both moved toward me, so I'll bank that before pushing back. Aggressive dropped the call-option language, treats 255 to 257 as a test instead of a sale level, and added a pre-earnings cut. Neutral conceded that a tranche belongs at 242 to 246. The argument is no longer whether to trim. It's whether the plan reduces risk on the paths we're likely to see, and I don't think it does yet.

Aggressive, your odds math works against you. 250 is 3.9% away and 227 is 5.7% away, which makes the stock about 60/40 to tag 250 first. I get 59.5%, so that's right for a driftless walk. But that is also why you called waiting versus selling now a wash in expectation. If expectation is a wash, variance breaks the tie, and variance is my mandate. Look at the 40% branch. You've sold 10 to 15 points, you hold 85 to 90 percent when 227 breaks, and your trigger is a close below 227, so you execute the next morning. This stock has dropped from 269.78 to 249.32 in one session, about 7.6%, and from 218.80 to 204.02, about 6.8%. A 226 close followed by a 219 open isn't exotic. Your "bounded at 5.7%" is the best case for the exit, applied to almost the whole position.

You also said that at 25% we'd own nothing if it runs 51% again. But your plan says to consider rebuilding on a close above 257 with RSI over 50. You can't rebuild at 257 and also say lighter at 240 leaves us with nothing. Take twenty extra points sold. If the stock goes straight to 257 before the daily flips, I've given up about 1.4 points of position value. If it goes back to 192, I've saved about 4. I'm not claiming equal odds. I'm saying the payoffs aren't symmetric, and one side has a re-entry trigger while the other has a gap.

I also reject the double-counting charge. The stress budget exists for the day the exit doesn't fill, and you called 206 a catastrophe backstop yourself. The levels table shows nothing between 224.67 and 206.08, and 206 is a trend line, not a price the stock has defended.

Your December rule is the best new idea in the thread, but 60% is too high. Both big gaps were around 7%, and if they were earnings reactions, the next one is a print where cost-of-revenue growth has accelerated three quarters running. Neutral's stress formula puts a 20% gap on a 60% residual at 12 points of the position. I'd go in at 40 or less. And that rule says nothing about the window before then: the late-October FOMC (the date still needs checking), the Iran ceasefire question through October 31, and the November 3 midterms.

Neutral, "fix the exit, don't shrink the position" looks better on paper than in practice. Your 7 of upside is the 255 to 257 cluster, where the 200 SMA, 50 SMA and daily SuperTrend sit together, and your own plan sells on a rejection there. The 10 to 265 sits beyond it. Meanwhile the daily and monthly trends are down, RSI hasn't cleared 50 since mid-September, OBV is near its lows, and today's bounce came on volume 17% under average. So the realistic reward is about 7 on a coin flip, and the realistic risk is 7 plus slippage with a gap tail. That's not a bad bet, just not one that deserves 60%.

Your 227 and 224.67 cuts are also only 2.33 points apart, about 1%. On any gap they fire together, so the plan is really one cut from 60 to a quarter. Say so, and take it at 227, where the higher low breaks.

Unknowns cut both ways in the stock, not in the book. If I trim too much, there's a visible trigger to rebuy. If I hold too much, the trigger is a gap. And if the 10-Q is the cheapest information in this debate, read it today, not before the second tranche.

I'll concede some balance sheet points. I can't tie the 29% current liabilities figure to the table, which shows about 13% over November 2024 and 16.5% over November 2025. You're right that cash excludes short-term investments and total assets are flat near $30B, so some of the cash decline and the $1.9B investing outflow may be reallocation. I'll drop those. What stands is liabilities up 37% since 2023, equity down 29%, and financing outflows near 89% of operating cash flow to fund a 7% share count reduction. That's affordable now, but it leaves less cushion if cash flow disappoints.

On valuation, a fifth for stock comp is a guess because the data doesn't itemize it, but I'll accept an 8% yield. Cheap isn't a catalyst, though. HSBC rates it Hold with a $267 target, 11% above here. My reading, which is interpretation, not data, is that an analyst who sees 11% upside and still says Hold is telling you 11% doesn't pay for the risk.

On macro, "priced in" is true of the level and false of the change. 97% no cuts is a level. The hike market moved up five points in a week to 82% on hot inflation, and with a beta of 1.4 a 5% market drop is roughly 7% on ADBE, which lands near 224.

So here is what I'd do, in percent of a full position. Go to about two-thirds now through 246 and about half at 248 to 251. Treat 255 to 257 as a test, and go to a third on a rejection. Go to a quarter on a volume close under 227, without waiting for 224.67. Go into the December print at 40 or less. Run the stress test, residual weight times 20%, against your single-name loss limit before each event, not only at the end. Rebuild in steps if the daily flips above 257 with RSI over 50. Proceeds stay in cash or short paper until someone names the better idea, and if you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Neutral, I reran your first-rung arithmetic and it holds, so I'll stop arguing about it. Twenty points sold at 240.68 instead of 250 costs about three-quarters of a point if the stock rallies and saves a bit over a point if 227 goes first. At 60/40 those cancel. My 1.4 versus 4 comparison only worked if no exit fills, which is a gap argument, not a first-rung argument. You're also right that "variance breaks the tie" proves too much, since cash always has the least variance. So I'll take about 75 through 246.

Aggressive's fix for my 226-close, 219-open scenario is better than my version too. I'd make it mechanical, though. A rule that depends on judging whether volume is heavy at 3:45 gets argued with on the day it matters. A resting stop a touch under 227 is cleaner, and I accept that it fills at the open on a gap.

The rest isn't a wash, and it all comes down to gaps.

Aggressive, you said we've already spent most of the variance budget by agreeing to carry forty to fifty points less than a full position. We haven't. Those points only get sold if the stock rallies into the ladder. In the branch you gave 40% odds, where 227 breaks first, the stock never reaches 248, so we're at 80 or 90 when the cut happens. The ladder sells strength, and the risk sits in the branch with no strength.

On the print, the stop is irrelevant, because prints are exactly where exits fail. The position going in is just weight times the gap. Your case for 50 was that a 13x stock showing opex convergence won't gap down. But the stock gapped to 204 in June at roughly eleven times the earnings we have now. Cheap didn't prevent a 25M-share day. I'll grant the upside gap is the same size in the other direction, so I won't claim 40 beats 50 on expectation. My claim is that none of us should be picking this number. Percent of a full position isn't a risk number. If a caller's full position is 10% of the book, half is 5%, and a 20% gap costs 1%. If the full position is 4%, half is 2%, and the gap costs 0.4%. So run the formula first: residual weight as a share of the book, times 20%, against the single-name loss limit. If it says less than the ladder, the formula wins. The trader's own 1% rule is that formula with a limit plugged in.

Aggressive, your Semrush recollection is the most useful thing added lately, and I have the same memory with the same caveat: unverified. If it's right, it cuts against holding more. A deal that size would add a few hundred million a year of revenue, perhaps a point or two of the 12.9% in Q3. Organic growth would then look closer to last year's 10.5% than to an acceleration. The same fact that softens the 23-cent story weakens the growth story that the case for holding rests on. Even the good-news reading of the filing takes something from the people who want to carry more.

That's why I'd read the 10-Q today, not before the second rung. It's public, and an hour of reading beats another round of guessing. I'd look for what the $1.9B was, what sits between $181M of operating income growth and $55M of net income growth, and how much stock comp there is. I'd also add a date nobody has put down: when the fiscal Q3 report came out. My recollection, which is memory, is mid-September, and our data doesn't date it. If it came before September 14, the 13% slide from 265.6 to 231 happened without a print. That's a much bigger non-earnings drawdown than the downgrade episode Neutral used as a test, which was 2.5%. If it came after, the stock sold off hard on the margin numbers we're debating. I don't think either answer helps the case for carrying half into December.

On rebuilding, I'm fine with it, but in thirds. The stock closed at 265.6 on September 14, comfortably above 257, and was at 231 two weeks later. One close above the cluster isn't a trend change. A close and a hold on a retest is closer.

So here's mine, in percent of a full position:

Sell about ten now, and go to roughly 75 through 246.
Go to about 55-60 at 248-251.
Go to about 40 on a rejection at 255-257.
Make one cut to 25-30 on a break of 227, using a mechanical stop.
Go into the December print at about 40. I'd move that to 50 only if the filing explains the gap between operating and net income and the formula allows it.
Rebuild in thirds on a close above 257 that holds on a retest.
Proceeds stay in cash or short paper until someone names a better use.
If you hold nothing, don't initiate.

Where the loss-limit formula gives a smaller number than any of these, take the smaller one.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: We're close enough now that I'll say what I'm taking, then argue the few places where I think the plan is still looser than it should be.

I'm taking 75 to 80 through 246, 60 at 248 to 251, and splitting the difference at 45 on a rejection. I accept one cut to 30 with no volume filter, and I accept the close-based trigger. I'd add two practical amendments. Entry for the closing auction shuts about ten minutes before the bell, so the rule in practice is "below 227 at 3:50," and someone has to be there to send it. The backstop also has to be a plain stop that becomes a market order, because a stop-limit is the order that doesn't fill on a gap. On 222 versus 224, Aggressive is right that 224 sits 67 cents under a wick we've already seen. I'll take 222, since the difference is a fraction of a point of position value. I also accept that the loss-limit formula is the override, which Aggressive has now said outright.

Now the disagreements. The first is the print stress, and Neutral, I think you cut it too far. You moved from 20% to 12% because the biggest single session anyone cited was 7.6%. But the June break in our data isn't a single session. There's a 17.8M-share day at 218.80, then 204.02 on 25M shares, the heaviest volume in the dataset, then an intraday low of 190.12 a week later. From 218.80 to 190.12 is about 13%, and that doesn't count the first day's drop, whose starting price we can't see. The one print we can examine in detail ran past 12% even without day one. Two prints is a thin sample, so I won't insist on 20, but I wouldn't go below 15. At a one percent limit, that's roughly 6.5 to 7 percent of the book going into the report, not 8. Aggressive, the 5 and the 8 also aren't two separate allowances. The position carries slide risk all the way to December and gap risk at the report, so it has to pass both, and the lower number binds until the report is out.

The second point is where the close-based exit actually fills. A close below 227 is 1.7% under the lowest close of the whole consolidation. With ATR at 3.4% of price, that's an ordinary day, and in the branch where the trigger fires we are probably selling around 224 to 226, not 227. When the caller runs the formula, they should budget the exit at about 225, which is 6.5% below here, not 5.7%.

Third, the rebuild. Aggressive, the V from 193 to 293 started at a record-volume capitulation near 190. A flip from here would come after weeks of closes between 231 and 242, in a tape where the daily and monthly trends are both down. The first rebuilt third would be bought at about 258, with the September 14 resistance at 265 to 266 only 3% overhead. If the daily line trails price by the 6% it trails by now, that is 3% of reward against 6% of risk, which is worse than the odds we just declined on the way up. So I'd keep the first tranche small and do the real buying on the hold, as Neutral said.

I'll also be honest about what being wrong costs. If the stock runs straight to 293 and we rebuild only to 78, my arithmetic puts the miss at five or six points of position value against never trading. It isn't a point or two. If the stock instead breaks 227 with us at 85 or 90, the exit costs about the same, around five and a half points. So when the exits work, the two branches cost about the same. The asymmetry lives entirely in the gap case, and that is the argument for carrying less. It's about the tail, not about where the levels sit.

Fourth, the proceeds. You both say cash or short paper, and I'd make it explicit that this excludes another high-beta, long-duration software or AI name. Part of what we're cutting is rate and multiple risk on a beta of 1.4. The retail talk of rotating out of chips into software is the same bet, so redeploying there would leave the exposure in place.

Last, the 10-Q. We all agree it's public and should be read today, and I'd tie the plan to it. It sets the December weight and the rebuild cap. The questions are what the 1.9B outflow was, what sits in the roughly 126M between operating income growth and net income growth, how much stock comp there is, and when the Q3 report landed. If it landed before September 14, the 13% slide to September 28 had no print behind it, and that is a much bigger non-event drawdown than the downgrade episode.

My plan, in percent of a full position, with every number a ceiling. Sell about ten now and ten more into 244 to 246, landing at 75 to 80. Go to 60 at 248 to 251, and to about 45 on a rejection at 255 to 257. Make one cut to about 30 on a close below 227 at the 3:50 check, with a plain stop near 222 as the backstop, and budget the exit at about 225. Rebuild small on a daily flip with a close above both averages, and do the real buying on a hold, capped at 75 to 80. Go into December at 50 or less, or 40 if the filing says the squeeze is organic or the formula doesn't clear, using a print shock of at least 15%. Run the formula before the FOMC once the date is confirmed, before November 3 and before the print, and take the smaller number. If you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Aggressive, the most important line in your last turn is that the formula runs on the weight actually held today, and that if it fails you sell to the passing weight at market instead of waiting for 246. I'll take that, because it changes what the ladder is. The ladder is no longer the plan for everyone. It's the plan for callers who already pass the test, and everyone else sells today. Your "sell down to 30, not sell 30 points" wording is also right, and so is Neutral's rider that the budget is 222 if nobody can send the close order at 3:50. Budget for the mechanism that will actually run.

I still push back on the idea that anything beyond the formula is a second premium on bounded risk. The risk is only bounded by the shock you plug in and the frame you plug it into.

On the shock, 17 percent to 200 is the gentlest number on the table. The June intraday low of 190.12 is 21 percent below here, so the allowed weight is closer to 5 percent of the book than 5.9. There's also the slide from the 265.6 close on September 14 to 231.01 on September 28, which is 13 percent in two weeks. Adobe's usual calendar puts the fiscal Q3 report around the second week of September, though I can't confirm that from here. If so, that slide came after the print with no catalyst I can name. I can't see the individual days, but ATR was 11 then, so it wasn't a quiet drift. I'd use 20 percent for the standing test. The difference is under a point of book weight, and it's the number the chart gave us.

On the frame, the formula is single-name and doesn't know what else the caller owns. We all agreed proceeds shouldn't go into another high-beta, long-duration software name, because that rebuilds the factor. The same logic applies to what's already in the book. Anything else that sells off on higher yields or the AI-disruption headline loses on the same day. I don't have portfolio context, so treat the formula's output as a ceiling, not a target.

On the rebuild probe, your 30 percent break-even is right if the payoff is the run from 258 to 293. But the first thing overhead after a flip is 265 to 266, which is where the September 14 bounce died, just under the 200 SMA at 266.34. Ten points bought at 258 earn about a third of a point to 266 and lose about six tenths if the flip fails. The break-even to 266 alone is about two in three. The probe only pays if you believe in the tail beyond that level. I'm not saying skip it. I'd make it five points and put the real money on the hold, which costs a fraction of a point and matches Neutral's own condition.

Neutral, I'll take your accounting. The middle of the distribution is cost-neutral and the benefit is in the tails, which is the case for taking the tails seriously. You're also right that there's no contrarian halo here. We're selling after a downgrade into down daily and monthly trends, with moderate conviction.

On December, "50 or less, or 40 if organic" leaves the default open, and the default is what happens if nobody reads the filing. None of us can read it from here. Your balance-sheet check fits an acquisition and fits $1.9 billion of short-term investment purchases equally well, and the two readings point opposite ways on whether the squeeze is organic. Until someone knows which, the plan should sit on the lower branch. Make 40 the default and let the filing earn the extra ten points, which by your own numbers is worth about a point. Aggressive's December falsifier is also observed on print day, which is the day exits can't help, so it can't protect the position going in. Only the filing and the weight going in can.

On proceeds, I agree cash is a default. De-risking doesn't need a destination to justify it. With the hike market pricing more tightening, short paper isn't dead money, though FRED failed, so I have no yield to quote.

Before the upper rungs are likely to fill, there are three dated risks. The late-October FOMC is still unconfirmed, though I recall October 27 to 28. The Iran ceasefire window runs through October 31, where an 80 percent market still leaves a one-in-five miss. The midterms are November 3. Run the formula before each one, on the weight held at that moment, and take the lower number.

So my plan, in percent of a full position, with every number a ceiling:

Sell about ten now, or straight down to the passing weight if that's lower.
Sell ten more into 244 to 246, landing at 75 to 80.
Go to 60 at 248 to 251, and to about 45 on a rejection at 255 to 257.
Make one cut to 30, written as "sell down to 30." Use a market-on-close order sent by 3:50 if the stock is below 227, plus a stop-market near 222, with each cancelling the other. Budget the exit at 225 or 222 depending on which mechanism the caller can run.
Keep the weekly 206 as the last line for a small core, not a target.
Run the standing stress at 20 percent and the print stress at 15 percent, both on the weight held, and the lower number binds.
Go into December at 40 until the filing is read.
Rebuild in thirds, starting with a five-point probe on a daily flip and a close above both averages. Put the real buying on the hold, capped at 75 to 80, with levels reset weekly.
Keep proceeds out of the same factor.
If you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL

Neutral Analyst¶

Neutral Analyst: Before I take either of you on, notice how much you agree on: trim, don't short, don't exit entirely. You split on how fast to sell, how much to keep, and what a range break should trigger. Each of you is right about one thing and wrong about another.

Aggressive first. You frame the risk-reward from 250, where the stop is 9% away and the upside is 6%. We're at 240.68. From here the 227 stop is about 5.7% down, the 255-257 cluster is about 7% up, and your own 265 target is about 10% up. That's roughly even to the cluster and better than 1.7 to 1 to 265, though 265 sits through resistance. So "holding the middle of the range earns nothing" is overstated. It's a good reason to prefer selling at 250, not a reason to treat this as a bad hold.

Your 206 hard exit has a similar problem. It's a trend-follower's line 14% away, so it works as a catastrophe backstop, not risk control. Calling the residual a call option doesn't help, because a call has a capped loss and this doesn't.

You also pick your growth number to suit the argument. "A 3% net income grower" is the expensive framing, "revenue accelerating" is the fine framing. Operating income grew about 8% in Q3, and operating cash flow and FCF are up about 11% over nine months. The gap between operating income and net income sits below the line, and we don't know why. Your 23-cent flow-through does hold up on nine months, at about 26 cents by my arithmetic, so it isn't a blip. But operating margin has gone 37.8, 33.8, 34.8, which isn't a clean downtrend.

Your volume comparison is lopsided too. The 17M and 25M days look like earnings reactions given when Adobe usually reports, though the data doesn't label them. Today's 3.48M is only about 17% under the ten-day average. And "proceeds go to better asymmetry" names nothing.

Conservative, you're right that the 255-257 tranche is a hope, not a plan. But 248-251 isn't a stretch. ATR is 8.26, so 250 is about one average day's range above us, and the stock tagged 248.3 on October 1. Selling a big chunk at 240 gives away the middle of the range, where the payoff is best. One tranche into 242-246 is cheap insurance, but a big one is overpaying.

Your cost arithmetic is the best point in this debate. I reran it and it checks. About 16 cents of each new revenue dollar is cost of revenue, about 61 cents is operating expense growing roughly 15%, and gross margin explains 60 of the 150 basis points of compression. So the AI-delivery story is under half of the problem. But you conclude that unknowns argue for carrying less, and unknowns cut both ways. Opex growth is also something management can dial back. The quarter closed August 28, so the 10-Q is almost certainly public by now. The gaps cost the price of reading a filing, so don't size around what you can look up.

On the residual, you shrink it to 2-2.5% of the book to make the 206 or 190 downside tolerable. I'd fix the exit, not shrink the position. If the residual exits at 224-227, the negative skew largely disappears, because you risk 6-7% to make 7-10%. Your 190 stress case also treats the June low as a base case when the big gaps look like earnings days, and the next one is December. And "missing 15% is bounded" is comfortable until you remember the stock rose 51% in two months this summer.

Several of your balance sheet points are over-read:

The cash decline excludes short-term investments, which this data doesn't show.
I can't reconcile the 29% current liabilities figure to the table, which shows about 13% above November 2024.
Haircut the FCF by a fifth for stock comp and the yield is still around 8%.
A net 7% share count decline means buybacks are more than absorbing dilution.

You both overreach on macro. A 97% no-cut market is already in the price, and the risk is a surprise at CPI or the FOMC. The stock has held 231-242 through a hot inflation week and a downgrade. HSBC went to Hold with a $267 target, which is 11% above here. That's a debate about durability, not a call for collapse.

So here's the plan, in percent of a full-size position since I don't know the book.

Now through about 246: sell down to roughly 75%. This is the concession to Conservative.
At 248-251: sell down to roughly 60%.
At 255-257: treat this as a test, not a sale level. A close above 257 with RSI over 50 and better volume means the daily trend flipped. Hold, and consider rebuilding. A rejection back under 250 means going to about 50%.
A volume close below 227: go to about 40%.
A close below 224.67: go to a quarter or less, with the weekly 206 as the last line for a small core.
Stress test: multiply the residual weight by roughly 20%, the gap to the mid-190s. If that exceeds your single-name loss limit, start from a smaller number.

Before the second tranche, read the 10-Q, pull consensus, and confirm the FOMC date and the CEO transition. Then re-underwrite before the December print. Don't pay in advance for risks the tape hasn't shown, but commit now to paying when it does. If you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to roughly 60%, with pre-set cuts on breakdown, and not an exit) Neutral Analyst: Before I get into the details, I want to point out that the two of you are now arguing about very little. The first rung is 67% for Conservative and 87% for Aggressive, and that's a 20-point slice of the position. If it tags 250 first, selling that slice at 240.68 instead of 250 costs about 0.8 of a point of position value. If it breaks 227 first, having sold it saves about 1.1. Weight those 60/40, as you both did, and you get 0.47 against 0.46. The first rung is worth about half a point either way. The pre-print weight and the exit discipline matter far more.

Conservative, "variance breaks the tie" proves too much. Applied consistently, it says sell everything, because variance is always lower in cash. The only reason to hold any residual is that expected return is positive: revenue growing 12-13%, FCF margin near 40%, about an 8% yield even after a stock comp haircut, and a weekly trend that's still up. The real question is how much variance that return justifies, and that's a sizing question, not a tiebreaker.

Your 1.4 versus 4 comparison has the same problem. The 4 assumes the stock goes to 192 with no exit working. If the 227 exit fills, the extra 20 points saves about 1.1, which is roughly the 1.4 you'd give up on the upside. The asymmetry only exists if exits fail, and that happens on gaps. The two big breaks in the data fall right after the dates Adobe usually reports, though nothing labels them, and the August 27 gap in the technical report is one I can't place. The best recent test of a non-earnings shock was the downgrade, a hot inflation week and a chip scare. It took the stock from the 242.27 close on the ninth to 236.28 on the thirteenth, about 2.5%. That is a lot less than the 7% moves you're citing.

Also, from here it's 5.7% down to 227 and 6.8% up to 257. That's roughly even before slippage, not "7 plus a gap tail" against 7. The 82% hike market is $0.78M deep, so a five-point weekly move there is a weak basis for sizing. I do agree with you on two things. Merging the 227 and 224.67 cuts is right, since they're 1% apart and would fire together. And the event windows matter.

Aggressive, going to 85-90% and holding through the weakest part of the structure isn't a trim. The daily and monthly trends are down, RSI is under 50, OBV is near its lows, and price is under both averages. Your own odds math says waiting is a wash in expectation, and the gap tail only goes one way, so that argues for a little more selling now, not less. Your "we'd own nothing" line also contradicts your rebuild rule. Rebuilding at 258 after selling at 240 costs about 7% on the slice, and that's a bounded price, not a disaster. Finally, you said December is a test of your thesis, that opex converging means 23 cents becomes 35 and you're wrong. You don't carry 60% into a test where you've said you could be wrong and have no edge on the outcome.

Here is where I land, in percent of a full position. Go to about 75% through 246. Go to about 60% at 248-251. At 255-257, a close above 257 with RSI over 50 and better volume means hold and rebuild in steps, but only toward 75-80%, because the monthly trend is still down. A rejection back under 250 takes you to 50%. On a volume close under 227, make one cut to about 30%, with the weekly 206 as the last line for a small core. Going into the December print, hold no more than about half. If you're still at 75% because nothing has triggered, sell down to half a week or two before. The stress test is residual weight times 20%, and it should be run before each event, as Conservative says, not just at the end.

Before the second tranche, read the 10-Q. One check is worth more than most of this debate. In Q3, operating income grew $181M but net income grew only $55M, so about $126M of new leakage sits between them. That's bigger than the gross margin story. It could be a tax item, lower interest income on a smaller cash pile, or something one-time. Nobody here knows, and it decides whether the net income growth we keep citing is real. Also pull consensus, confirm the FOMC date, and check the CEO and CFO transitions. And if you hold nothing, don't initiate.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim to roughly 60%, with pre-set cuts on breakdown and a smaller position into the December print, not an exit) Neutral Analyst: We're down to a few real differences, so I'll take a side on each. Most of what's left is noise, or one of you leaning on something that doesn't quite hold.

First the noise. Seventy-five versus eighty through 246 is five points of position over a four percent move, about a fifth of a point. Fifty-five versus sixty at 248-251 is nothing. Fifty versus forty after a rejection at 255-257 is ten points over roughly ten percent to the cut, about one point. I'd split that at 45 and move on.

Now the stop, where each of you has half the answer. Aggressive, "heavy volume in the last fifteen minutes" is exactly the rule Conservative says gets argued with on the day it matters, and he's right. Conservative, a resting intraday stop just under 227 has already been tested by this tape. On September 28 the stock printed 224.67 intraday and closed at 231.01. A stop at 226.5 sells that wick, and then you watch the stock get back to 242 without you. So I'd drop the volume filter, since a quiet break of a higher low is still a break. I'd also drop the intraday trigger at 227. Make it mechanical on price alone: if it's below 227 into the close, a market-on-close order sells, and nobody has to judge anything. Then add an intraday backstop just under 224, below the swing low and the 2-ATR level, for the day it never gives you a close to act on. That's one cut to about 30 with two triggers, whichever fires first. If it gaps through both, you take the open, which Conservative already accepted.

Conservative, I also have to correct your September 14 example. You said the stock closed at 265.6, comfortably above 257, and was at 231 two weeks later. But on September 14 the 200 SMA was 266.34, so 265.6 was below it. That wasn't a failed breakout of today's cluster. It was a rejection at the 200 SMA with RSI at 50.56. It still supports waiting for a hold before rebuilding. It also shows the levels drift. The 200 SMA has fallen about eleven points in a month and will keep falling as higher closes from last winter roll off. Even at half that pace it's near 252 in two weeks, which puts the cluster right on top of the second rung. So write the rebuild trigger as a daily SuperTrend flip with a close above both averages, whatever the numbers are that day, and reset the levels weekly. Rebuild in thirds, as Conservative says, but cap it at 75-80, as Aggressive says, because the monthly trend is still down.

On December, I'd settle it this way: cap it at half and let the formula pull it lower. Conservative, your loss-limit formula is already the override, so a separate default of 40 counts the same protection twice. But the stress number needs fixing, and that's partly my doing. The 20% I gave was for a multi-day slide through the exits. I shouldn't have let it migrate onto a print, where the biggest single-session drop anyone has cited is about 7.6%. For a print I'd use roughly 12%, about one and a half times the worst on record, because two or three data points is a thin sample. At 12%, fifty points costs six points of position value and forty costs under five. The whole disagreement is about 1.2 points. So the cap is 50, and it drops to 40 if the 10-Q says the squeeze is organic or the formula doesn't clear.

Aggressive, your December falsifier is too narrow. Opex growth converging is one line item. As I recall, Adobe gives next year's targets with its Q4 report, but that's unconfirmed. If so, the stock trades on the FY27 guide and on any evidence about Firefly monetization or seat pressure. A print can show opex converging and still gap down on a soft guide. It can also look messy and rally because the guide is fine. The 10-Q is the homework, the guide is the event, and that's one more reason not to carry more than half in.

On Semrush, I have the same memory and the same caveat. Two things from the tables, not from memory. First, nine-month investing outflow was 1.91B against 1.04B a year earlier, so the year-over-year increase is only about 0.87B. A deal near 1.9B would normally push that higher, unless it was net of acquired cash or other investment flows went the other way. The data doesn't tie neatly, so I wouldn't lock in the explanation. Second, if the deal closed after the February quarter, Q1's 12.0% growth is probably organic and already above last year's 10.5%. That means the re-acceleration started before any deal. Stripping a lower-margin acquired business out of both revenue and cost of revenue narrows the gap between 18.8% and 12.9%, but I don't see it closing the gap by itself. Don't change today's action over it.

On the 10-Q, Conservative is right that I said before the second tranche, and there's no reason to wait. Read it today. Look for what the 1.9B was, what sits in the roughly 126M between operating and net income growth, how much stock comp there is, and when the fiscal Q3 report actually landed. That date matters for how we read the September slide.

One housekeeping point. Every number here is a "go to" ceiling. If you're already below a rung, you don't sell more there and you don't buy. If you hold nothing, don't initiate.

Here's where I land, in percent of a full position:

Sell about ten now and ten more into 244-246, landing at 75-80.
Go to 60 at 248-251.
Go to about 45 on a rejection at 255-257.
Make one cut to about 30 on a close below 227 or a trade under 224, with no volume filter.
Rebuild in thirds on a daily SuperTrend flip and a close above both averages that holds on a retest, capped at 75-80.
Go into December at 50 or less, or 40 if the filing says the squeeze is organic or the loss formula requires it.
Run the residual-weight stress before each event: the late-October FOMC once the date is confirmed, the November 3 midterms, and the print.
Proceeds stay in cash or short paper until someone names something better.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim, not an exit) Neutral Analyst: We agree on today's action, so I'll start there. All three of us sell about ten points now. Everything after that is conditional, and most of what's left in dispute is rounding.

Aggressive, I'd push back on two things. First, "a point or two of position value" is the cost of the first rung only. Conservative's whole-plan number is closer, and I reran it. If we sell about 40 points near 246 and the stock runs straight to 293, that's roughly 7.5 points forgone. Rebuilding 18 points at 258 claws back about 2.5, so the net miss is around five. The other branch costs about the same: breaking 227 with us at 85 or 90 means giving up about 5.5 points on the decline. So in the middle of the distribution this plan is roughly cost-neutral. The benefit is in the tails. I'd defend that, but it isn't a cheap option, and a plan sold as cheap gets sized too loosely.

Second, the bold, against-the-crowd framing doesn't hold up. The retail lean is seven bullish and two bearish on-topic tags from five authors in one session, and the sell-side just downgraded. Selling after a downgrade into down daily and monthly trends is going with the news flow. The contrarian move is the director's purchase at 194. That doesn't change the action, but moderate conviction means we shouldn't borrow confidence from a story about fading the crowd.

Conservative, you're right that the print test and the slide test aren't two separate allowances, and I'd go further. The trader's own rule sizes the residual for a gap to about 200, a 17% move. That is stricter than any print shock anyone has proposed, so for anyone who passes it, the print test never binds. At a 1% limit the number that binds all the way to December is the 5 to 6 percent of the book. The December weight on the ladder only matters for callers with room to spare, and for them the 40-versus-50 gap is worth about a point. I'll take 15% for the print check anyway. Two observations is thin and it costs about 1.5 points on a 50-point position. But 218.80 to 190.12 includes a week of drift after the gap that the exits would have caught, so I wouldn't lean on it as proof.

I also accept budgeting the close-based exit at about 225, but with a practical rider. If nobody can send the order at 3:50, the stop-market near 222 is the only trigger, and the budget is 222, about 7.8% below here, not 225. Budget for the mechanism the caller can actually run. On proceeds, I agree they shouldn't go into another high-beta, long-duration software name. But the rule is about not recreating the factor. A caller with a target allocation can rebalance into whatever is underweight outside that bucket.

On rebuilding, you're both arguing over a few tenths of a point again. Your 3% reward to 266 against 6% risk is right if you only count the next resistance. But the reason to buy a flip is the right tail, not the first level. A third of a 30-point rebuild is 10 points, so a failed first third costs about 0.6 points. I'd take Aggressive's thirds with Conservative's condition: the first third needs a daily SuperTrend flip and a close above both averages, wherever the 200 SMA has drifted to. The second waits for a hold on a retest, and the third for weekly follow-through.

On Semrush, I checked the balance sheet and it doesn't discriminate. Non-cash assets are up about $1.56B since November 2025 while cash is down $1.07B. That fits an acquisition's goodwill, but it fits $1.9B of short-term investment purchases just as well, and the data doesn't show those separately. The two readings cut opposite ways. If it was an acquisition, organic growth and the margin squeeze both look different. If it was investments, cash and net debt are overstated, and the squeeze and the growth are organic. Each of you gains or loses depending on which it is, so the filing should gate everything past the first rung and set the December weight.

Here is where I land, in percent of a full position, with every number a ceiling: - Sell about ten now and ten more into 244 to 246, landing at 75 to 80. - Go to 60 at 248 to 251. - Go to about 45 on a rejection under 250 after a test of 255 to 257. - Make one cut to about 30 on a sub-227 close at the 3:50 check, with a stop-market near 222 as the backstop. - Rebuild in thirds as above, capped at 75 to 80, with levels reset weekly. - Go into December at 50 or less, or 40 if the 10-Q says the squeeze is organic. - Run the residual-weight stress, 17 to 20% for standing risk, before the FOMC once the date is confirmed, before November 3, and before the print. The smaller number wins. - If you hold nothing, don't initiate.

This beats both extremes. The aggressive version sells mostly into hoped-for strength, and the conservative version pays for insurance in the middle of the range. This one sells a little now, sells more into strength, cuts hard on a break, and keeps the weekly-uptrend exposure.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim, not an exit) Neutral Analyst: We've agreed on the structure, so I'll say what I'm taking from each of you and where each of you still leans too hard.

The loss-limit formula is the cap, and it runs on the weight actually held today. The ladder is the view, and it only operates inside the cap. If you fail the test, you sell to the passing weight now. If you pass, you still sell about ten on the view and ten more into strength. Every number is a ceiling, so if the stock opens at 245 you go straight to the 75 to 80 rung, and if you're already below a rung you do nothing. Nobody should argue about that anymore.

Aggressive, you're right that a lower December number, a heavier print shock and extra mid-range selling, all stacked on the caller's own limit, would be paying twice for the same tail. But I have two problems with your last turn.

The first is that 17 percent is the trader's round number, while 190.12 is on the chart, 21 percent below. The gap between 5.9 and 5.0 percent of the book is under a point of weight, so I'd run the standing test at 20.

The second is that you treat the filing as a dial on December: 50 if it's acquisition noise, 40 if it's organic. But the filing speaks directly to your thesis, which is 23 cents of incremental margin. Suppose the $126M gap between operating and net income is a one-time or tax item, and the $1.9B outflow was an acquisition that explains the cost-of-revenue acceleration. Then the 248-251 and 255-257 rungs would be selling on a view the filing just took away, and only the formula would still justify them. So I'd let a clean filing cancel the thesis-driven rungs, not just move December by ten points. It wouldn't make me rebuy the first ten, since the daily and monthly trends are still down, but it would stop the ladder from running on autopilot. If the squeeze is organic, the ladder runs as written and December is 40.

Conservative, I'll take 40 as the December default. It costs about a point on everyone's arithmetic, and the filing can earn the other ten. You're also right that a falsifier observed on print day can't protect a position going in. And the formula is a ceiling, not a target. It doesn't know the rest of the book, and we can't invent a number for that, so we say it and move on.

But the September slide is doing more work in your argument than it should. ATR of 11 on the fourteenth describes the days before the fourteenth, not the slide after. That slide also bottomed at a 231.01 close, 1.7 percent above the 227 trigger. Repeat a 13 percent slide from here and the stock goes through 227 on the way down, and the exit sells around 225. So that slide is evidence for the exit budget, not for a bigger gap shock. The case for 20 percent rests on the June sequence and the 190 low, and that's enough. If someone later argues for 25, the September slide shouldn't be the proof.

On the rebuild probe, five points versus ten is another fraction-of-a-point argument. What neither of you has said is what exits the probe. A position bought on a flip with no stop is an open-ended loss, which is exactly what this debate has been trying to avoid on the way down. So size the probe by its loss. A failed flip is a close back under the 255-257 cluster, a 6 to 7 percent give-back from about 258. Cap that at about a third of a point of position value, which works out to roughly five points. Aggressive gets his probe, Conservative gets his size, and the second third waits for a hold.

I have three practical notes. - The data is last night's close, so everything keys to the rungs, not the clock. - Routine insider entries will likely show up around today and the 24^th. Those look like vesting and tax withholding, not signals, so nobody should trade a headline about them. - The dated-risk list needs a fourth entry: Adobe's own late-October or November event, which one retail post mentions and I can't verify. The rule is the same as for the others: run the formula beforehand and don't guess the news.

So here is the plan, with every number a ceiling, in percent of a full position. Sell about ten now, or straight down to the passing weight if that's lower, and ten more into 244 to 246, landing at 75 to 80. Go to 60 at 248 to 251, and to about 45 on a rejection under 250 after a test of 255 to 257. Make one cut to 30, written as "sell down to 30", on a below-227 reading at the 3:50 check, with a stop-market near 222 behind it and each order cancelling the other. Budget the exit at 225 or 222, depending on which mechanism the caller can actually run. Run the standing stress at 20 percent and the print stress at 15 percent on the weight held, before the FOMC once the date is confirmed, before the Iran deadline on October 31, before November 3, before any Adobe event and before the print, and take the smaller number. Go into December at 40 until the filing earns 50. Rebuild in thirds, starting with a probe of about five points on a daily flip and a close above both averages, with a close back under the cluster as its exit. Add the second third on a hold and the third on weekly follow-through, capped at 75 to 80, with levels reset weekly. Keep proceeds out of the same rate-and-AI factor. If you hold nothing, don't initiate.

This isn't the cheap option Aggressive first sold, or the extra insurance Conservative wants on top of the caller's own limit. It costs about five points in the middle of the distribution either way. In return it caps the tail at a number the caller chose, and the 10-Q decides how much of the ladder is a view and how much is only risk management.

FINAL TRANSACTION PROPOSAL: SELL (a staged trim, not an exit)

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Underweight ADBE. Existing holders should trim in stages, not exit. Do not initiate or chase a breakout, and do not short. All rungs below are ceilings in percent of a standard position: sell about 10 points now; go to 75-80 into 244-246; go to 60 at 248-251; go to about 45 on a rejection back under 250 after a test of 255-257; make one cut to 30 on a close below 227 (market-on-close sent by 3:50) or a stop-market near 222, written as 'sell down to 30' with each order cancelling the other; and go into the mid-December Q4 print at 40 or less until the Q3 10-Q is read. Before each event (FOMC, Oct 31, Nov 3, any Adobe event, the print), size the position you actually hold so a 20% shock to about 190 stays within your single-name loss limit (about 1% of the book). If it fails that test, sell to the passing weight today at market. Horizon is about 2-3 months, through the Q4 print.

Investment Thesis: Decision: Underweight, executed as a staged trim. The research manager, the trader and all three risk analysts agree on direction: reduce, don't exit, don't short. My job is to settle the sizing disputes.

Why not Sell or exit. Revenue growth is accelerating: +12.0%, +12.7%, +12.9% across FY26 quarters, and +12.5% for nine months. Gross margin is ~88.7%. Nine-month OCF is $7.65B (+11.3%) and FCF ~$7.47B. The stock trades at ~13.2x GAAP TTM EPS of $18.24, with ~8% FCF yield even after Neutral's one-fifth SBC haircut. The share count is shrinking ~7% a year. The weekly SuperTrend (primary tier) is still UP, with its stop at 206.08. Nothing in the packet shows revenue or cash flow breaking, and even the most bearish voices said explicitly that they are not short.

Why not Hold or Buy. Profitability is weakening against revenue: - Only ~23 cents of Q3's extra $772M of revenue reached operating income (~26c over nine months). - Cost-of-revenue growth accelerated 6.8% → 12.1% → 18.8%, and gross margin slipped 89.6% → 89.2% → 88.7%. - Conservative's decomposition, which Neutral reran, shows ~61c of each lost 77c is opex, growing ~15% against 12.9% revenue. The problem is broader than AI delivery cost. - Q3 operating income grew $181M but net income only $55M. That ~$126M leak is unexplained, and EPS growth of +10.5% leaned on buybacks against net income growth of +3.1%. - The bear's at-trend Q4 projection (op margin ~34.3%, net income ~flat, EPS +~8% mostly from buybacks) fails the bull's own ~10% EPS hurdle.

The tape does not argue for adding either. Price is 240.68, ~6% below the 255.3-257.0 cluster (200 SMA 255.26, daily SuperTrend 256.93, 50 SMA 257.00). Daily and monthly SuperTrends are DOWN. RSI is 46.56 and has not cleared 50 since Sep 14. OBV is near its lows. The bounce came on 3.48M shares against a ~4.2M average. The 50/200 cross is cosmetic, because the 200 SMA fell into price.

Macro and the Street add pressure. Beta is 1.415, the market shows 97% odds of no cuts and 82% odds of a hike (the latter in a thin, ~$0.78M market), and HSBC has just downgraded to Hold with a $267 target, citing AI disruption.

Settling the sizing disputes: - First rung: Neutral's pricing showed it is worth ~half a point either way. Across the whole ladder, the middle of the distribution is roughly cost-neutral (~5 points of position value missed in each branch). The real benefit is in the tails, which is exactly why trimming is justified. - Selling now vs. waiting: Conservative's strongest point is that the ladder sells strength, while the risk sits in the branch with no strength. So about 10 points are sold now, and the loss-limit formula runs on the weight held today. Aggressive conceded both. - Shock size: I adopt Conservative's 20% standing shock, because the June low of 190.12 is 21% below. The trader's 17% to 200 is gentler. I use 15% for the print. - December default: 40, until the filing earns 50. - Exit triggers: I adopt Neutral's price-only 227 close trigger without a volume filter (this supersedes the research plan's volume condition), plus Aggressive's 222 backstop. A 224 stop would sit only 67 cents under the Sep 28 wick, which closed at 231.01. - Rebuild: on a daily SuperTrend flip with a close above both averages (levels reset weekly, since the 200 SMA is drifting down), buy a ~5-point probe that exits on a close back under the cluster. Add the second third on a hold of the retest and the last third on weekly follow-through, capped at 75-80 because the monthly trend is down. - Proceeds: cash or short paper, not another high-beta, long-duration software/AI name.

What changes the call. Read the Q3 10-Q now for four things: - what the $1.9B investing outflow was. The recalled Semrush deal is unverified, and the yoy increase is only ~$0.87B. - what explains the $126M operating-to-net gap. - SBC. - any ARR or subscription disclosure change.

How the filing moves the plan: - A clean one-time or tax explanation can cancel the thesis-driven upper rungs and allow 50 into December. - A disclosure change cuts to 0-25.

Q4 print triggers: - Two or more of these mean near-zero weight: op margin below 35.0%, gross margin below ~88.5%, incremental op margin below 20%, NI/OI below 76%, or an FY27 guide with a lower margin. - Restore to standard weight (Overweight only if price confirms) if all of these hold: cost step of $25M or less, gross margin 88.7% or better, op margin 35.5% or better, and net income growth of 5% or more. - A second disruption downgrade with estimate cuts halves what remains.

Price target ($239), probability-weighted on GAAP EPS: - Derived Q4 FY25 EPS = 18.24 − (4.60 + 4.25 + 4.62) = 4.77. At-trend +8% gives ~5.15, so post-print TTM EPS ≈ 18.62. - Above trend, 45%: ~14.2x ≈ $265 (the flat-multiple objective, near HSBC's $267). - At trend, 30%: 12.5x × 18.62 ≈ $233. This is a modest de-rate from 13.2x as the bull thesis fails. - Below trend, 25%: ~11x × 18.3 ≈ $201 (the June-type multiple). - The probabilities follow the bear's ~55% odds of two or more triggers firing. - 0.45×265 + 0.30×233 + 0.25×201 ≈ $239.4, call it $239, or about −0.7% from 240.68.

That is a roughly cash-like expected return with a −17% to −21% left tail on a 1.4-beta stock, which is the case for Underweight rather than Hold.

Confidence is medium. The fundamentals are intact and several key items are missing: the 10-Q, consensus, options pricing, and confirmed dates for the FOMC, the print, the CEO/CFO transition and Adobe MAX.

Current Price: 240.68

Price Target: 239.0

Confidence: Medium

Time Horizon: 2-3 months